STIC Search Report
Biotech-Chem Library

STIC Database Tracking Number: 163985

TO: Ralph J Gitomer
Location: 3d65/3c18
Art Unit: 1655
Wednesday, August 03, 2005

Case Serial Number: 10/785042

From: Noble Jarrell
Location: Biotech-Chem Library
Rem 1B71
Phone: 272-2556

Noble.jarrell@uspto.gov

Search Notes

```
=> d his

     (FILE 'HOME' ENTERED AT 10:29:56 ON 03 AUG 2005)

     FILE 'HCAPLUS' ENTERED AT 10:30:03 ON 03 AUG 2005
L1            1 (US2004167214 OR US2002022245)/PN

     FILE 'REGISTRY' ENTERED AT 10:31:10 ON 03 AUG 2005

     FILE 'HCAPLUS' ENTERED AT 10:31:12 ON 03 AUG 2005
L2              TRA L1 1- RN :        3 TERMS

     FILE 'REGISTRY' ENTERED AT 10:31:12 ON 03 AUG 2005
L3            3 SEA L2

     FILE 'WPIX' ENTERED AT 10:31:14 ON 03 AUG 2005
L4            1 L1

=> b hcap
FILE 'HCAPLUS' ENTERED AT 10:31:32 ON 03 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 3 Aug 2005  VOL 143 ISS 6
FILE LAST UPDATED: 2 Aug 2005  (20050802/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> d all l1

L1   ANSWER 1 OF 1  HCAPLUS  COPYRIGHT 2005 ACS on STN
AN   2002:89890  HCAPLUS
DN   136:129027
ED   Entered STN:  01 Feb 2002
TI   Drug screening method for the treatment and prophylaxis of obesity
IN   Hebebrand, Johannes; Antel, Jochen; Preuschoff, Ulf; David, Samuel; Sann,
     Holger; Weske, Michael
PA   Solvay Pharmaceuticals G.m.b.H., Germany
SO   PCT Int. Appl., 27 pp.
     CODEN: PIXXD2
DT   Patent
LA   German
IC   ICM  A61P001-00
     ICS  G01N033-50
CC   1-1 (Pharmacology)
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    -------------------    --------
PI   WO 2002007821        A1    20020131    WO 2001-EP8051         20010712
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM,
```

HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,
RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN,
YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

DE	10035227	A1	20020131	DE 2000-10035227	20000720
CA	2416647	AA	20030120	CA 2001-2416647	20010712
EP	1307262	A1	20030507	EP 2001-955345	20010712
EP	1307262	B1	20041006		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

BR	2001012547	A	20030701	BR 2001-12547	20010712
JP	2004504053	T2	20040212	JP 2002-513551	20010712
AT	278441	E	20041015	AT 2001-955345	20010712
NZ	523960	A	20041224	NZ 2001-523960	20010712
ES	2230346	T3	20050501	ES 2001-1955345	20010712
US	2002022245	A1	20020221	US 2001-907440	20010718 <--
ZA	2003000444	A	20040416	ZA 2003-444	20030116
NO	2003000233	A	20030319	NO 2003-233	20030117
US	2004167213	A1	20040826	US 2004-785042	20040225
US	2004167214	A1	20040826	US 2004-785043	20040225 <--

PRAI	DE 2000-10035227	A	20000720
	US 2000-219672P	P	20000721
	WO 2001-EP8051	W	20010712
	US 2001-907440	A3	20010718

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002007821	ICM	A61P001-00
	ICS	G01N033-50
WO 2002007821	ECLA	C12Q001/527
DE 10035227	ECLA	C12Q001/527
JP 2004504053	FTERM	2G045/BB01; 2G045/BB51; 2G045/CB01; 2G045/FB01; 2G045/FB08; 4B063/QA01; 4B063/QA05; 4B063/QA18; 4B063/QQ08; 4B063/QR18; 4B063/QR77; 4B063/QS36; 4B063/QX07; 4C084/AA17; 4C084/NA14; 4C084/ZA702
US 2002022245	NCL	435/026.000
	ECLA	C12Q001/527 <--
US 2004167213	NCL	514/517.000
	ECLA	C12Q001/527
US 2004167214	NCL	514/517.000
	ECLA	C12Q001/527 <--

AB The invention relates to a method for screening compds. that can be used for the treatment and prophylaxis of obesity; the ability of the screened compds. to inhibit de novo lipogenesis in mammals and humans is determined Also disclosed is the use of compds. which are capable of inhibiting de novo lipogenesis in mammals in the production of drugs for the treatment and/or prophylaxis of obesity. Compds. that inhibit carboanhydrase subtypes II and V are selected by using adipocytes, hepatocytes or genetically produced enzymes. Selected compds. are also tested for anticonvulsant activity. Expts. with topiramate are reported.

ST drug screening obesity lipogenesis carboanhydrase inhibition topiramate antiobesity agent

IT Adipose tissue
(adipocyte; drug screening method for treatment and prophylaxis of obesity)

IT Anticonvulsants
Antiobesity agents
Drug screening
Human
Obesity
(drug screening method for treatment and prophylaxis of obesity)

IT Lipids, biological studies
RL: PAC (Pharmacological activity); BIOL (Biological study)

(formation of; drug screening method for treatment and prophylaxis of obesity)
IT Liver
(hepatocyte; drug screening method for treatment and prophylaxis of obesity)
IT 452-35-7, Ethoxzolamide 97240-79-4, Topiramate
RL: PAC (Pharmacological activity); BIOL (Biological study)
(drug screening method for treatment and prophylaxis of obesity)
IT 9001-03-0, Dehydratase, carbonate
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibition of; drug screening method for treatment and prophylaxis of obesity)
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Genentech Inc; WO 9409813 A 1994 HCAPLUS
(2) Hellerstein, M; EUROPEAN JOURNAL OF CLINICAL NUTRITION 1999, V53(1), P53
(3) Supuran, C; EXPERT OPINION ON THERAPEUTIC PATENTS V10(5), P575 HCAPLUS

=> b reg

FILE 'REGISTRY' ENTERED AT 10:31:40 ON 03 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 2 AUG 2005 HIGHEST RN 857941-82-3
DICTIONARY FILE UPDATES: 2 AUG 2005 HIGHEST RN 857941-82-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

```
**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,    *
* effective March 20, 2005. A new display format, IDERL, is now      *
* available and contains the CA role and document type information. *
*                                                                    *
**********************************************************************
```

Structure search iteration limits have been increased. See HELP SLIMITS
for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> d ide l3 tot

L3 ANSWER 1 OF 3 REGISTRY COPYRIGHT 2005 ACS on STN
RN **97240-79-4** REGISTRY
ED Entered STN: 21 Jul 1985
CN β-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, sulfamate
(9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 5H-Bis[1,3]dioxolo[4,5-b:4',5'-d]pyran, β-D-fructopyranose deriv.
OTHER NAMES:

CN 2,3:4,5-Bis-O-(1-methylethylidene) β-D-fructopyranose sulfamate
CN McN 4853
CN RWJ 17021
CN Topamax
CN Topiramate
CN Topomax
FS STEREOSEARCH
MF C12 H21 N O8 S
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CIN, CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, PATDPASPC, PHAR, PROMT, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

686 REFERENCES IN FILE CA (1907 TO DATE)
13 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
692 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 2 OF 3 REGISTRY COPYRIGHT 2005 ACS on STN
RN **9001-03-0** REGISTRY
ED Entered STN: 16 Nov 1984
CN Dehydratase, carbonate (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Anhydrase
CN Carbonate anhydrase
CN Carbonate dehydratase
CN Carbonic acid anhydrase
CN Carbonic anhydrase
CN Carboxyanhydrase
CN E.C. 4.2.1.1
DR 9044-52-4, 9052-41-9
MF Unspecified
CI MAN
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DDFU, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PROMT, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

9515 REFERENCES IN FILE CA (1907 TO DATE)
314 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
9530 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 3 OF 3 REGISTRY COPYRIGHT 2005 ACS on STN
RN **452-35-7** REGISTRY
ED Entered STN: 16 Nov 1984
CN 2-Benzothiazolesulfonamide, 6-ethoxy- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)
OTHER NAMES:
CN 6-Ethoxy-2-benzothiazolesulfonamide
CN Cardrase
CN Diuretic C
CN Ethamide
CN Ethoxyzolamide
CN Ethoxzolamide
CN Etoxzolamide
CN Glaucotensil
CN L 643786
CN NSC 10679
CN PNU 4191
CN Redupresin
CN U 4191
FS 3D CONCORD
MF C9 H10 N2 O3 S2
CI COM
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, PS, RTECS*, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

272 REFERENCES IN FILE CA (1907 TO DATE)
10 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
272 REFERENCES IN FILE CAPLUS (1907 TO DATE)
23 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> b wpix

FILE 'WPIX' ENTERED AT 10:31:45 ON 03 AUG 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE LAST UPDATED: 2 AUG 2005 <20050802/UP>
MOST RECENT DERWENT UPDATE: 200549 <200549/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE, PLEASE VISIT:

```
 http://www.stn-international.de/training_center/patents/stn_guide.pdf <<<

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
    http://thomsonderwent.com/coverage/latestupdates/          <<<

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER
    GUIDES, PLEASE VISIT:
    http://thomsonderwent.com/support/userguides/              <<<

>>> NEW! FAST-ALERTING ACCESS TO NEWLY-PUBLISHED PATENT
    DOCUMENTATION NOW AVAILABLE IN DERWENT WORLD PATENTS INDEX
    FIRST VIEW - FILE WPIFV.
    FOR FURTHER DETAILS: http://www.thomsonderwent.com/dwpifv  <<<

>>> THE CPI AND EPI MANUAL CODES HAVE BEEN REVISED FROM UPDATE 200501.
    PLEASE CHECK:
http://thomsonderwent.com/support/dwpiref/reftools/classification/code-revision/
    FOR DETAILS. <<<
'BIX BI,ABEX' IS DEFAULT SEARCH FIELD FOR 'WPIX' FILE

=> d all l4 tot

L4   ANSWER 1 OF 1  WPIX  COPYRIGHT 2005 THE THOMSON CORP on STN
AN   2002-180498 [24]   WPIX
DNC  C2002-056198
TI   Selection and use of lipogenesis inhibitors for the treatment and
     prevention of obesity.
DC   B05
IN   ANTEL, J; DAVID, S; HEBEBRAND, J; PREUSCHOFF, U; SANN, H; WESKE, M
PA   (SOLV) SOLVAY PHARM GMBH; (ANTE-I) ANTEL J; (DAVI-I) DAVID S; (HEBE-I)
     HEBEBRAND J; (PREU-I) PREUSCHOFF U; (SANN-I) SANN H; (WESK-I) WESKE M
CYC  97
PI   DE 10035227     A1 20020131 (200224)*       6    A61K031-7004
     US 2002022245   A1 20020221 (200224)            C12Q001-32     <--
     WO 2002007821   A1 20020131 (200224)  GE        A61P001-00
        RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ
            NL OA PT SD SE SL SZ TR TZ UG ZW
         W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM
            DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ
            LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD
            SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW
     AU 2001077534   A  20020205 (200236)            A61P001-00
     NO 2003000233   A  20030319 (200328)            C12Q001-34
     EP 1307262      A1 20030507 (200332)  GE        A61P001-00
         R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
            RO SE SI TR
     SK 2003000061   A3 20030603 (200345)            A61P001-00
     CZ 2003000156   A3 20030618 (200347)            G01N033-50
     KR 2003022284   A  20030315 (200350)            C12Q001-32
     BR 2001012547   A  20030701 (200356)            A61P001-00
     CN 1443085      A  20030917 (200382)            A61P001-00
     HU 2003002309   A2 20031128 (200405)            A61P001-00
     JP 2004504053   W  20040212 (200413)       37   C12Q001-527
     US 2004167213   A1 20040826 (200457)#           A61K031-255
     US 2004167214   A1 20040826 (200457)#           A61K031-34     <--
     MX 2002012907   A1 20030901 (200465)            A61P001-00
     EP 1307262      B1 20041006 (200466)  GE        A61P001-00
         R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC NL PT RO SE
            SI TR
     DE 50104023     G  20041111 (200474)            A61P001-00
     NZ 523960       A  20041224 (200506)            C12Q001-527
     ES 2230346      T3 20050501 (200532)            A61P001-00
ADT  DE 10035227 A1 DE 2000-10035227 20000720; US 2002022245 A1 Provisional US
     2000-219672P 20000721, US 2001-907440 20010718; WO 2002007821 A1 WO
     2001-EP8051 20010712; AU 2001077534 A AU 2001-77534 20010712; NO
     2003000233 A WO 2001-EP8051 20010712, NO 2003-233 20030117; EP 1307262 A1
```

EP 2001-955345 20010712, WO 2001-EP8051 20010712; SK 2003000061 A3 WO 2001-EP8051 20010712, SK 2003-61 20010712; CZ 2003000156 A3 WO 2001-EP8051 20010712, CZ 2003-156 20010712; KR 2003022284 A KR 2003-700620 20030115; BR 2001012547 A BR 2001-12547 20010712, WO 2001-EP8051 20010712; CN 1443085 A CN 2001-812973 20010712; HU 2003002309 A2 WO 2001-EP8051 20010712, HU 2003-2309 20010712; JP 2004504053 W WO 2001-EP8051 20010712, JP 2002-513551 20010712; US 2004167213 A1 Div ex US 2001-907440 20010718, US 2004-785042 20040225; US 2004167214 A1 Div ex US 2001-907440 20010718, US 2004-785043 20040225; MX 2002012907 A1 WO 2001-EP8051 20010712, MX 2002-12907 20021219; EP 1307262 B1 EP 2001-955345 20010712, WO 2001-EP8051 20010712; DE 50104023 G DE 2001-00104023 20010712, EP 2001-955345 20010712, WO 2001-EP8051 20010712; NZ 523960 A NZ 2001-523960 20010712, WO 2001-EP8051 20010712; ES 2230346 T3 EP 2001-955345 20010712

FDT AU 2001077534 A Based on WO 2002007821; EP 1307262 A1 Based on WO 2002007821; SK 2003000061 A3 Based on WO 2002007821; CZ 2003000156 A3 Based on WO 2002007821; BR 2001012547 A Based on WO 2002007821; HU 2003002309 A2 Based on WO 2002007821; JP 2004504053 W Based on WO 2002007821; MX 2002012907 A1 Based on WO 2002007821; EP 1307262 B1 Based on WO 2002007821; DE 50104023 G Based on EP 1307262, Based on WO 2002007821; NZ 523960 A Based on WO 2002007821; ES 2230346 T3 Based on EP 1307262

PRAI DE 2000-10035227 20000720; US 2004-785042 20040225; US 2004-785043 20040225

IC ICM A61K031-255; A61K031-34; A61K031-7004; A61P001-00; C12Q001-32; C12Q001-34; C12Q001-527; G01N033-50

ICS A61K045-00; A61P003-00; A61P003-04; A61P003-06; C12Q001-02; G01N033-15; G01N033-68

AB DE 10035227 A UPAB: 20020416

NOVELTY - Compounds for the treatment and/or prevention of obesity are selected on the basis of their capability to inhibit de novo lipogenesis in mammals.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for the use of compounds which are capable of inhibiting de novo lipogenesis in mammals and which have no anticonvulsant activity for the production of a medicament for the treatment and/or prevention of obesity.

ACTIVITY - Anorectic.

MECHANISM OF ACTION - Lipogenesis inhibitor; Carboanhydrase inhibitor.

No biological data given.

USE - For the treatment and prevention of obesity (claimed).

ADVANTAGE - The method is simple, rapid and avoids protracted and expensive in vivo tests, including feeding experiments on animals.

Dwg.0/0

FS CPI

FA AB

MC CPI: B11-C08E3; B12-K04A; B14-E12

=> b home
FILE 'HOME' ENTERED AT 10:31:53 ON 03 AUG 2005

=>

```
=> d his full

     (FILE 'HOME' ENTERED AT 10:29:56 ON 03 AUG 2005)

     FILE 'HCAPLUS' ENTERED AT 10:30:03 ON 03 AUG 2005
L1             1 SEA ABB=ON  PLU=ON  (US2004167214 OR US2002022245)/PN

     FILE 'REGISTRY' ENTERED AT 10:31:10 ON 03 AUG 2005

     FILE 'HCAPLUS' ENTERED AT 10:31:12 ON 03 AUG 2005
L2             TRA L1 1- RN :         3 TERMS

     FILE 'REGISTRY' ENTERED AT 10:31:12 ON 03 AUG 2005
L3             3 SEA ABB=ON  PLU=ON  L2

     FILE 'WPIX' ENTERED AT 10:31:14 ON 03 AUG 2005
L4             1 SEA ABB=ON  PLU=ON  (US2004167214 OR US2002022245)/PN

     FILE 'HCAPLUS' ENTERED AT 10:35:58 ON 03 AUG 2005
                E ADIPOSE TISSUE/CT
                E E3+ALL
L5         41716 SEA ABB=ON  PLU=ON  ADIPOSE TISSUE+NT/CT
                E E13+ALL
L6         23346 SEA ABB=ON  PLU=ON  OBESITY+NT/CT
                E E7+ALL
L7          6210 SEA ABB=ON  PLU=ON  ANTIOBESITY AGENTS+OLD/CT
                E APPETITE/CT
                E E3A+LL
                E APPETITE/CT
                E E3+ALL
L8         15243 SEA ABB=ON  PLU=ON  APPETITE+NT/CT
                E APPETITE DEPRESSANTS/CT
                E E3+ALL
L9          2373 SEA ABB=ON  PLU=ON  APPETITE DEPRESSANTS+OLD/CT
                E BODY WEIGHT/CT
                E E3+ALL
L10        19434 SEA ABB=ON  PLU=ON  BODY WEIGHT/CT
                E LIPIDS/CT
                E E3+OLD,NT1
L11             QUE ABB=ON  PLU=ON  LIPIDS+OLD,NT1/CT
L12        152074 SEA ABB=ON  PLU=ON  LIPID#/CW
L13         31294 SEA ABB=ON  PLU=ON  (L11 OR L12) (L)FORMAT?
                E LIPOGENESIS/CT
L14          4657 SEA ABB=ON  PLU=ON  LIPOGENES?
L15         34708 SEA ABB=ON  PLU=ON  DRUG SCREENING+OLD/CT
L16            28 SEA ABB=ON  PLU=ON  L15 AND (L13 OR L14)
L17            19 SEA ABB=ON  PLU=ON  L16 AND (L5 OR L6 OR L7 OR L8 OR L9 OR
               L10)
L18            17 SEA ABB=ON  PLU=ON  L17 AND (?INHIBIT? OR ?MODULAT? OR ?BLOCK?
               OR ?PREVENT? OR ANTAGON?)
L19             QUE ABB=ON  PLU=ON  PY<=2001 OR AY<=2001 OR PRY<=2001 OR
               PD<20010718 OR AD<20010718 OR PRD<20010718
L20            12 SEA ABB=ON  PLU=ON  L18 AND L19
                E HEBEBRAND J/AU
L21            96 SEA ABB=ON  PLU=ON  ("HEBEBRAND J"/AU OR "HEBEBRAND JOHANNES"/A
               U)
                E ANTEL J/AU
L22            83 SEA ABB=ON  PLU=ON  ("ANTEL J"/AU OR "ANTEL J P"/AU OR "ANTEL
               JOCHEN"/AU)
                E PREUSCHOFF U/AU
L23            18 SEA ABB=ON  PLU=ON  "PREUSCHOFF ULF"/AU
                E SANN H/AU
L24           247 SEA ABB=ON  PLU=ON  ("SANN H"/AU OR "SANN H J"/AU OR "SANN
               HOLGER"/AU)
                E WESKE M/AU
L25            8 SEA ABB=ON  PLU=ON  ("WESKE M"/AU OR "WESKE MICHAEL"/AU)
```

```
                E SOLVAY/CS,PA
L26          4044 SEA ABB=ON  PLU=ON  SOLVAY/CS,PA
L27             1 SEA ABB=ON  PLU=ON  L18 AND (L21 OR L22 OR L23 OR L24 OR L25
                  OR L26)
L28            11 SEA ABB=ON  PLU=ON  L20 NOT L27
L29            10 SEA ABB=ON  PLU=ON  ("131:98053"/AN OR "133:129884"/AN OR
                  "133:159935"/AN OR "136:227973"/AN OR "137:210957"/AN OR
                  "137:257694"/AN OR "137:43447"/AN OR "139:79155"/AN OR
                  "139:81326"/AN OR "142:171141"/AN OR "1999:454261"/AN OR
                  "2000:548711"/AN OR "2000:573930"/AN OR "2002:172081"/AN OR
                  "2002:466175"/AN OR "2002:675784"/AN OR "2002:736796"/AN OR
                  "2003:511096"/AN OR "2003:511950"/AN OR "2005:99131"/AN) AND
                  L11

     FILE 'REGISTRY' ENTERED AT 11:08:16 ON 03 AUG 2005
L30             1 SEA ABB=ON  PLU=ON  L3 AND DEHYDRA?
                  D SCA
L31             0 SEA ABB=ON  PLU=ON  CARBOANHYDRAS?/CNS
L32           543 SEA ABB=ON  PLU=ON  DEHYDRATAS?(1A)CARBONAT?

     FILE 'HCAPLUS' ENTERED AT 11:10:06 ON 03 AUG 2005
L33          9530 SEA ABB=ON  PLU=ON  L30
L34          9645 SEA ABB=ON  PLU=ON  L32
L35         11627 SEA ABB=ON  PLU=ON  CARBOANHYDRASE? OR ANHYDRASE OR CARBOXYANHY
                  DRASE OR "E.C.4.2.1.1" OR "EC4.2.1.1" OR (E(1A)C OR EC)(1A)"4.2
                  .1.1" OR DEHYDRATAS?(1A)CARBON?
L36             0 SEA ABB=ON  PLU=ON  (L33 OR L34 OR L35) AND L29
L37             1 SEA ABB=ON  PLU=ON  (L33 OR L34 OR L35) AND L27
L38           102 SEA ABB=ON  PLU=ON  (L33 OR L34 OR L35) AND L15
                  D QUE L18
L39            81 SEA ABB=ON  PLU=ON  L38 AND (?INHIBIT? OR ?MODULAT? OR ?BLOCK?
                  OR ?PREVENT? OR ANTAGON?)
L40             3 SEA ABB=ON  PLU=ON  L38 AND (L5 OR L6 OR L7 OR L8 OR L9)
L41             2 SEA ABB=ON  PLU=ON  L39 AND L40
L42             1 SEA ABB=ON  PLU=ON  L41 AND (L21 OR L22 OR L23 OR L24 OR L25
                  OR L26)
L43             1 SEA ABB=ON  PLU=ON  L41 NOT L42
L44             1 SEA ABB=ON  PLU=ON  (L27 OR L37 OR L42)
L45            11 SEA ABB=ON  PLU=ON  (L29 OR L43)

=>  b hcap
FILE 'HCAPLUS' ENTERED AT 11:17:25 ON 03 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 3 Aug 2005  VOL 143 ISS 6
FILE LAST UPDATED: 2 Aug 2005  (20050802/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> d all l44 tot
```

L44 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:89890 HCAPLUS
DN 136:129027
ED Entered STN: 01 Feb 2002
TI Drug screening method for the treatment and prophylaxis of obesity
IN **Hebebrand, Johannes**; **Antel, Jochen**; **Preuschoff, Ulf**; David, Samuel; **Sann, Holger**; **Weske, Michael**
PA **Solvay** Pharmaceuticals G.m.b.H., Germany
SO PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DT Patent
LA German
IC ICM A61P001-00
ICS G01N033-50
CC 1-1 (Pharmacology)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002007821	A1	20020131	WO 2001-EP8051	20010712
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	DE 10035227	A1	20020131	DE 2000-10035227	20000720
	CA 2416647	AA	20030120	CA 2001-2416647	20010712
	EP 1307262	A1	20030507	EP 2001-955345	20010712
	EP 1307262	B1	20041006		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001012547	A	20030701	BR 2001-12547	20010712
	JP 2004504053	T2	20040212	JP 2002-513551	20010712
	AT 278441	E	20041015	AT 2001-955345	20010712
	NZ 523960	A	20041224	NZ 2001-523960	20010712
	ES 2230346	T3	20050501	ES 2001-1955345	20010712
	US 2002022245	A1	20020221	US 2001-907440	20010718
	ZA 2003000444	A	20040416	ZA 2003-444	20030116
	NO 2003000233	A	20030319	NO 2003-233	20030117
	US 2004167213	A1	20040826	US 2004-785042	20040225
	US 2004167214	A1	20040826	US 2004-785043	20040225
PRAI	DE 2000-10035227	A	20000720		
	US 2000-219672P	P	20000721		
	WO 2001-EP8051	W	20010712		
	US 2001-907440	A3	20010718		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002007821	ICM	A61P001-00
	ICS	G01N033-50
WO 2002007821	ECLA	C12Q001/527
DE 10035227	ECLA	C12Q001/527
JP 2004504053	FTERM	2G045/BB01; 2G045/BB51; 2G045/CB01; 2G045/FB01; 2G045/FB08; 4B063/QA01; 4B063/QA05; 4B063/QA18; 4B063/QQ08; 4B063/QR18; 4B063/QR77; 4B063/QS36; 4B063/QX07; 4C084/AA17; 4C084/NA14; 4C084/ZA702
US 2002022245	NCL	435/026.000
	ECLA	C12Q001/527
US 2004167213	NCL	514/517.000
	ECLA	C12Q001/527
US 2004167214	NCL	514/517.000
	ECLA	C12Q001/527

AB The invention relates to a method for screening compds. that can be used for the treatment and prophylaxis of obesity; the ability of the screened compds. to **inhibit** de novo **lipogenesis** in mammals and humans is determined Also disclosed is the use of compds. which are capable of **inhibiting** de novo **lipogenesis** in mammals in the production of drugs for the treatment and/or prophylaxis of obesity. Compds. that **inhibit carboanhydrase** subtypes II and V are selected by using adipocytes, hepatocytes or genetically produced enzymes. Selected compds. are also tested for anticonvulsant activity. Expts. with topiramate are reported.

ST drug screening obesity **lipogenesis carboanhydrase inhibition** topiramate antiobesity agent

IT **Adipose tissue**
(adipocyte; drug screening method for treatment and prophylaxis of obesity)

IT Anticonvulsants
Antiobesity agents
Drug screening
Human
Obesity
(drug screening method for treatment and prophylaxis of obesity)

IT **Lipids, biological studies**
RL: PAC (Pharmacological activity); BIOL (Biological study)
(**formation** of; drug screening method for treatment and prophylaxis of obesity)

IT Liver
(hepatocyte; drug screening method for treatment and prophylaxis of obesity)

IT 452-35-7, Ethoxzolamide 97240-79-4, Topiramate
RL: PAC (Pharmacological activity); BIOL (Biological study)
(drug screening method for treatment and prophylaxis of obesity)

IT **9001-03-0, Dehydratase, carbonate**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(**inhibition** of; drug screening method for treatment and prophylaxis of obesity)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Genentech Inc; WO 9409813 A 1994 HCAPLUS
(2) Hellerstein, M; EUROPEAN JOURNAL OF CLINICAL NUTRITION 1999, V53(1), P53
(3) Supuran, C; EXPERT OPINION ON THERAPEUTIC PATENTS V10(5), P575 HCAPLUS

=> d all hitstr l45 tot

L45 ANSWER 1 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN
AN **2005:99131** HCAPLUS
DN 142:171141
ED Entered STN: 04 Feb 2005
TI Protein and cDNA sequences for human fibroblast growth factor-19 (FGF19) and methods of using FGF19 and FGFR4 for the treatment of obesity and related disorders
IN Adams, Sean; Goddard, Audrey; Gurney, Austin L.; John, Linu; Stewart, Timothy A.; Tomlinson, Elizabeth; Yu, Xing Xian
PA Genentech, Inc., USA
SO U.S. Pat. Appl. Publ., 79 pp., Cont.-in-part of U.S. Ser. No. 712,560.
CODEN: USXXCO
DT Patent
LA English
IC ICM A61K048-00
ICS A61K038-18; C12N015-85
INCL 514012000; 514044000; 435455000
CC 3-3 (Biochemical Genetics)
Section cross-reference(s): 1, 2, 13
FAN.CNT 123

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI US 2005026832 A1 20050203 US 2004-855211 20040526
WO 9927100 A1 19990603 WO 1998-US25190 19981125
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
ZA 9810781 A 20000525 ZA 1998-10781 19981125
NZ 528704 A 20050225 NZ 1999-528704 19990308
US 2002012961 A1 20020131 US 1999-284663 19990415
WO 2000015666 A2 20000323 WO 1999-US20594 19990908
WO 2000015666 A3 20001123
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
WO 2000015796 A2 20000323 WO 1999-US21090 19990915
WO 2000015796 A3 20000824
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
JP 2004507201 T2 20040311 JP 2000-570323 19990915
EP 1466977 A1 20041013 EP 2004-7618 19991202
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY
WO 2001005836 A1 20010125 WO 1999-US30999 19991220
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
NZ 523206 A 20041224 NZ 2000-523206 20000211
NZ 523207 A 20041224 NZ 2000-523207 20000211
NZ 517395 A 20040130 NZ 2000-517395 20000309
CA 2380355 AA 20010308 CA 2000-2380355 20000824
CA 2481685 AA 20010308 CA 2000-2481685 20000824
CA 2481691 AA 20010308 CA 2000-2481691 20000824
CA 2481731 AA 20010308 CA 2000-2481731 20000824
CA 2481756 AA 20010308 CA 2000-2481756 20000824
CA 2481788 AA 20010308 CA 2000-2481788 20000824
US 2002042367 A1 20020411 US 2001-767609 20010122
US 2002058309 A1 20020516 US 2001-866028 20010525
US 6642360 B2 20031104
CA 2419541 AA 20020228 CA 2001-2419541 20010530
JP 2004520811 T2 20040715 JP 2002-522282 20010530
US 2003108983 A1 20030612 US 2001-902572 20010710
US 2003113718 A1 20030619 US 2001-902979 20010710
US 2003104381 A1 20030605 US 2001-903823 20010711
US 2003130489 A1 20030710 US 2001-903806 20010711

US 2003148419	A1	20030807	US 2001-903603	20010711
US 6767995	B2	20040727		
US 2003187238	A1	20031002	US 2001-903562	20010711
US 2003113719	A1	20030619	US 2001-905125	20010712
US 6664376	B2	20031216		
US 2003135025	A1	20030717	US 2001-904992	20010712
US 2003152999	A1	20030814	US 2001-904766	20010712
US 2003211569	A1	20031113	US 2001-904938	20010712
US 2003129592	A1	20030710	US 2001-905449	20010713
US 2003148370	A1	20030807	US 2001-904838	20010713
US 2003152922	A1	20030814	US 2001-904532	20010713
US 2003166051	A1	20030904	US 2001-904920	20010713
US 6806352	B2	20041019		
US 2003113838	A1	20030619	US 2001-906815	20010716
US 2003148371	A1	20030807	US 2001-906777	20010716
US 2003190610	A1	20031009	US 2001-906618	20010716
US 6828146	B2	20041207		
US 2003215904	A1	20031120	US 2001-906722	20010716
US 2003104469	A1	20030605	US 2001-907652	20010717
US 2003190611	A1	20031009	US 2001-907728	20010717
US 2004005553	A1	20040108	US 2001-908576	20010718
AU 758921	B2	20030403	AU 2001-57764	20010801
AU 759004	B2	20030403	AU 2001-57765	20010801
US 2002155543	A1	20021024	US 2001-924647	20010807
CA 2420193	AA	20020228	CA 2001-2420193	20010823
JP 2004520810	T2	20040715	JP 2002-522275	20010823
US 2003207803	A1	20031106	US 2001-143026	20011019
US 2003170254	A1	20030911	US 2001-17191	20011024
US 2003199021	A1	20031023	US 2001-13924	20011025
US 2003032057	A1	20030213	US 2001-2796	20011115
EP 1397383	A2	20040317	EP 2001-990229	20011213
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003032062	A1	20030213	US 2002-66273	20020201
US 2003032063	A1	20030213	US 2002-66494	20020201
US 2003040014	A1	20030227	US 2002-66269	20020201
US 2003044902	A1	20030306	US 2002-66193	20020201
US 2003044844	A1	20030306	US 2002-66211	20020201
AU 772759	B2	20040506	AU 2002-14767	20020201
AU 772723	B2	20040506	AU 2002-14769	20020201
AU 772734	B2	20040506	AU 2002-14771	20020201
AU 778585	B2	20041209	AU 2002-14753	20020201
CA 2449602	AA	20021219	CA 2002-2449602	20020403
WO 2002101069	A2	20021219	WO 2002-US10513	20020403
WO 2002101069	A3	20030904		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1402260	A2	20040331	EP 2002-731246	20020403
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2005500030	T2	20050106	JP 2003-503819	20020403
US 2003148438	A1	20030807	US 2002-145821	20020514
US 2003170788	A1	20030911	US 2002-145634	20020514
US 2003166084	A1	20030904	US 2002-146793	20020515
US 2003134380	A1	20030717	US 2002-147509	20020516
US 2004214269	A1	20041028	US 2002-147518	20020516
US 2003180875	A1	20030925	US 2002-147505	20020517
US 2003199027	A1	20031023	US 2002-152396	20020520

	US 2005074837	A1	20050407	US 2002-158788	20020530
	US 2003068695	A1	20030410	US 2002-192012	20020709
	US 2003068696	A1	20030410	US 2002-192014	20020709
	US 2003049743	A1	20030313	US 2002-194394	20020711
	US 2003049745	A1	20030313	US 2002-194485	20020711
	US 2003064446	A1	20030403	US 2002-194460	20020711
	US 2003153037	A1	20030814	US 2002-194457	20020711
	US 2003059879	A1	20030327	US 2002-194456	20020712
	US 2003064448	A1	20030403	US 2002-194484	20020712
	US 2003049747	A1	20030313	US 2002-195899	20020715
	US 2003064449	A1	20030403	US 2002-195884	20020715
	US 2003063112	A1	20030403	US 2002-195896	20020715
	US 2003068705	A1	20030410	US 2002-195886	20020715
	US 2003068706	A1	20030410	US 2002-195891	20020715
	US 2003071834	A1	20030417	US 2002-195898	20020715
	US 2003049749	A1	20030313	US 2002-196750	20020716
	US 2003065159	A1	20030403	US 2002-196757	20020716
	US 2003068710	A1	20030410	US 2002-196761	20020716
	US 2003104547	A1	20030605	US 2002-197701	20020717
	US 2003104548	A1	20030605	US 2002-197706	20020717
	US 2003207398	A1	20031106	US 2002-198759	20020718
	US 2003215910	A1	20031120	US 2002-199463	20020718
	US 2003180881	A1	20030925	US 2002-202475	20020723
	US 2003064462	A1	20030403	US 2002-206919	20020726
	US 2003064463	A1	20030403	US 2002-206922	20020726
	US 2003068756	A1	20030410	US 2002-206912	20020726
	US 2003068759	A1	20030410	US 2002-206920	20020726
	US 2003068760	A1	20030410	US 2002-206921	20020726
	US 2003073183	A1	20030417	US 2002-206917	20020726
	US 2003096359	A1	20030522	US 2002-205910	20020726
	US 2004048334	A1	20040311	US 2002-205890	20020726
	US 2003068765	A1	20030410	US 2002-207916	20020729
	US 2003068766	A1	20030410	US 2002-207917	20020729
	US 2003068769	A1	20030410	US 2002-207920	20020729
	US 2003068773	A1	20030410	US 2002-208023	20020729
	US 2003068774	A1	20030410	US 2002-208026	20020729
	US 2003073184	A1	20030417	US 2002-207923	20020729
	US 2003073185	A1	20030417	US 2002-207924	20020729
	US 2003215912	A1	20031120	US 2002-207915	20020729
	US 2004048335	A1	20040311	US 2002-208024	20020729
	US 2003120056	A1	20030626	US 2002-289498	20021105
	US 2003144498	A1	20030731	US 2002-289527	20021105
	US 2004249141	A1	20041209	US 2002-289490	20021105
	US 2003224984	A1	20031204	US 2002-305654	20021126
	US 2003199044	A1	20031023	US 2003-410552	20030408
	US 2004146908	A1	20040729	US 2003-712560	20031112
	US 2004258710	A1	20041223	US 2004-791618	20040302
	US 2005009105	A1	20050113	US 2004-916250	20040811
	US 2005019823	A1	20050127	US 2004-931886	20040831
	US 2005153396	A1	20050714	US 2004-955952	20040929
	US 2005153348	A1	20050714	US 2004-20604	20041221
	US 2005164266	A1	20050728	US 2005-36582	20050113
	US 2005136515	A1	20050623	US 2005-56802	20050211
	US 2005136475	A1	20050623	US 2005-60652	20050216
	US 2005158830	A1	20050721	US 2005-80062	20050314
PRAI	US 1997-66840P	P	19971125		
	US 1998-158342	B1	19980921		
	WO 1998-US25190	A1	19981125		
	US 1999-284663	A2	19990415		
	WO 1999-US20594	A	19990908		
	WO 1999-US21090	A	19990915		
	WO 1999-US30999	A	19991220		
	US 2000-522342	B2	20000309		
	US 2001-767609	A2	20010122		
	US 2001-924647	A1	20010807		
	US 2003-712560	A2	20031112		

US 1997-56974P	P	19970826
US 1997-59115P	P	19970917
US 1997-59263P	P	19970918
US 1997-59588P	P	19970919
US 1997-62285P	P	19971017
US 1997-62816P	P	19971024
US 1997-63082P	P	19971024
US 1997-63327P	P	19971027
US 1997-63329P	P	19971027
US 1997-63541P	P	19971028
US 1997-63542P	P	19971028
US 1997-63544P	P	19971028
US 1997-63549P	P	19971028
US 1997-63550P	P	19971028
US 1997-63564P	P	19971028
US 1997-63435P	P	19971029
US 1997-63704P	P	19971029
US 1997-63732P	P	19971029
US 1997-63733P	P	19971029
US 1997-63734P	P	19971029
US 1997-63735P	P	19971029
US 1997-63738P	P	19971029
US 1997-64215P	P	19971029
US 1997-63870P	P	19971031
US 1997-64103P	P	19971031
US 1997-64248P	P	19971103
US 1997-64809P	P	19971107
US 1997-65186P	P	19971112
US 1997-65846P	P	19971117
US 1997-65693P	P	19971118
US 1997-66120P	P	19971121
US 1997-66364P	P	19971121
US 1997-66453P	P	19971124
US 1997-66466P	P	19971124
US 1997-66511P	P	19971124
US 1997-66770P	P	19971124
US 1997-66772P	P	19971124
US 1997-69425P	P	19971212
US 1997-69694P	P	19971216
US 1998-74086P	P	19980209
US 1998-74092P	P	19980209
US 1998-77649P	P	19980311
US 1998-79294P	P	19980325
US 1998-81049P	P	19980408
US 1998-82704P	P	19980422
US 1998-83742P	P	19980430
US 1998-85339P	A1	19980513
US 1998-87106P	P	19980528
US 1998-88026P	P	19980604
US 1998-88217P	P	19980605
US 1998-88655P	P	19980609
US 1998-89947P	P	19980619
US 1998-91982P	P	19980707
US 1998-94651P	A1	19980730
US 1998-95998P	P	19980810
US 1998-97000P	P	19980818
US 1998-97974P	P	19980826
US 1998-99601P	P	19980909
US 1998-99803P	P	19980910
US 1998-99811P	P	19980910
US 1998-99812P	P	19980910
WO 1998-US18824	W	19980910
AU 1998-93881	A3	19980914
US 1998-100262P	P	19980914
WO 1998-US19330	W	19980916
US 1998-100858P	P	19980917

US 1998-158432	A	19980921
US 1998-101922P	P	19980924
AU 1998-93178	A3	19981002
US 1998-104080P	P	19981013
US 1998-105169P	P	19981022
US 1998-106032P	P	19981028
US 1998-109304P	P	19981120
US 1998-216021	B1	19981216
US 1998-113296P	P	19981222
US 1998-218517	B1	19981222
US 1999-254311	A1	19990303
US 1999-125778P	P	19990323
US 1999-131293P	P	19990427
US 1999-139695P	P	19990615
US 1999-143048P	P	19990707
US 1999-144758P	P	19990720
US 1999-145070P	P	19990720
US 1999-145698P	P	19990726
US 1999-146222P	A1	19990728
US 1999-149395P	P	19990817
US 1999-380139	A1	19990825
US 1999-151689P	P	19990831
US 1999-920594	A	19990908
WO 1999-US20944	W	19990913
US 1999-921090	A	19990915
EP 1999-960644	A3	19991202
US 1999-169495P	P	19991207
US 1999-170262P	P	19991209
US 1999-99309	A	19991220
US 2000-175481P	P	20000111
US 2000-441400	A	20000222
WO 2000-US4414	W	20000222
US 2000-187202P	P	20000303
WO 2000-US6471	W	20000309
US 2000-191007P	P	20000321
US 2000-198121P	P	20000418
US 2000-198585P	P	20000418
US 2000-199397P	P	20000425
US 2000-199550P	P	20000425
US 2000-201516P	P	20000503
US 2000-204675P	P	20000517
US 2000-209832P	P	20000605
CA 2000-2380355	A3	20000824
US 2000-232887P	P	20000915
US 2000-690189	A3	20001016
US 2001-816920	B1	20010322
WO 2001-US17443	W	20010530
US 2001-880457	A	20010612
US 2001-904553	A2	20010713
WO 2001-US26626	W	20010823
US 2001-2796	A	20011115
WO 2001-US48938	W	20011213
US 2002-52586	A1	20020115
WO 2002-US10513	W	20020403
US 2002-123155	A1	20020415
US 2002-125166	A1	20020417
US 2002-127825	A1	20020422
US 2002-145627	A1	20020514
US 2002-145751	A	20020514
US 2002-199666	A1	20020718
US 2004-797366	A1	20040309

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2005026832	ICM	A61K048-00
	ICS	A61K038-18; C12N015-85

Search done by Noble Jarrell

	INCL	514012000; 514044000; 435455000
US 2005026832	NCL	514/012.000; 514/044.000; 435/455.000
WO 9927100	ECLA	C07K014/50
US 2002012961	NCL	435/069.100; 530/350.000; 530/399.000; 536/023.500; 435/320.100; 435/325.000
	ECLA	C07K014/50
WO 2000015666	ECLA	C07K014/47
WO 2000015796	ECLA	C07K014/47
JP 2004507201	FTERM	4B024/AA01; 4B024/AA11; 4B024/BA02; 4B024/BA03; 4B024/BA21; 4B024/BA31; 4B024/BA41; 4B024/BA43; 4B024/BA63; 4B024/CA04; 4B024/DA02; 4B024/DA06; 4B024/DA12; 4B024/EA02; 4B024/EA04; 4B024/GA11; 4B024/HA01; 4B024/HA15; 4B064/AG02; 4B064/AG13; 4B064/AG20; 4B064/AG27; 4B064/CA02; 4B064/CA06; 4B064/CA10; 4B064/CA19; 4B064/CC24; 4B064/DA01; 4B064/DA13; 4B065/AA26X; 4B065/AA72X; 4B065/AA90X; 4B065/AA93X; 4B065/AA93Y; 4B065/AB01; 4B065/AC14; 4B065/BA02; 4B065/CA24; 4B065/CA25; 4B065/CA44; 4B065/CA46; 4H045/AA10; 4H045/AA11; 4H045/AA30; 4H045/BA10; 4H045/CA40; 4H045/DA01; 4H045/DA20; 4H045/DA50; 4H045/DA76; 4H045/EA22; 4H045/EA28; 4H045/EA51; 4H045/EA54; 4H045/FA74
EP 1466977	ECLA	C07K016/18
WO 2001005836	ECLA	C07K014/47
US 2002042367	NCL	514/012.000; 435/069.400; 435/325.000; 536/023.500; 530/399.000; 514/044.000
	ECLA	C07K014/50
US 2002058309	NCL	530/350.000; 530/324.000
	ECLA	C07K014/47; C07K014/47A1A; C07K014/705R; C07K016/18
JP 2004520811	FTERM	2G045/AA34; 2G045/AA35; 2G045/BB05; 2G045/BB10; 2G045/BB14; 2G045/BB20; 2G045/BB29; 2G045/BB46; 2G045/BB50; 2G045/BB51; 2G045/CB01; 2G045/DA13; 2G045/FA29; 2G045/FB02; 2G045/FB03; 2G045/FB06; 2G045/FB12; 2G045/GC10; 2G045/GC15; 4B024/AA01; 4B024/AA11; 4B024/BA26; 4B024/CA02; 4B024/CA04; 4B024/DA02; 4B024/DA06; 4B024/DA12; 4B024/HA17; 4B063/QA18; 4B063/QA19; 4B063/QQ43; 4B063/QR55; 4B063/QR77; 4B063/QR80; 4B063/QS34; 4B064/AG03; 4B064/AG27; 4B064/CA02; 4B064/CA06; 4B064/CA10; 4B064/CA19; 4B064/CC24; 4B064/DA01; 4B064/DA13; 4B065/AA26; 4B065/AA72; 4B065/AA90; 4B065/AB01; 4B065/BA02; 4B065/CA24; 4B065/CA44; 4B065/CA46; 4C084/AA17; 4C084/DC50; 4C084/NA14; 4C084/ZA661; 4C085/AA14; 4C085/BB11; 4C085/CC02; 4C085/CC21; 4C086/AA01; 4C086/AA02; 4C086/EA16; 4C086/MA03; 4C086/MA05; 4C086/NA14; 4C086/ZA66; 4H045/AA10; 4H045/AA11; 4H045/AA20; 4H045/AA30; 4H045/BA10; 4H045/BA41; 4H045/CA40; 4H045/DA02; 4H045/DA76; 4H045/EA27; 4H045/FA74
US 2003108983	NCL	435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200
US 2003113718	NCL	435/006.000; 435/007.100; 435/069.100; 435/183.000; 435/325.000; 530/350.000; 530/388.100; 514/012.000; 536/023.200
US 2003104381	NCL	435/006.000; 435/007.100; 435/069.100; 435/183.000; 435/320.100; 435/325.000; 514/012.000; 530/350.000; 536/023.200
US 2003130489	NCL	536/023.100
US 2003148419	NCL	530/387.100; 530/350.000; 530/387.900; 530/388.100
US 2003187238	NCL	536/023.100
US 2003113719	NCL	530/350.000; 435/219.000
US 2003135025	NCL	530/350.000; 435/006.000; 435/320.100; 435/325.000; 435/183.000; 435/069.100; 514/012.000; 530/388.100; 536/023.200; 435/007.100
US 2003152999	NCL	435/007.100; 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 530/388.100; 536/023.200;

		514/012.000
US 2003211569	NCL	435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200
US 2003129592	NCL	435/006.000; 435/007.100; 435/069.100; 435/183.000; 435/320.100; 435/325.000; 514/012.000; 530/350.000; 530/388.100; 536/023.200
US 2003148370	NCL	435/007.100; 435/069.100; 435/183.000; 435/325.000; 435/320.100; 514/012.000; 530/350.000; 530/388.100; 536/023.200
US 2003152922	NCL	435/006.000; 435/007.100; 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 514/012.000; 536/023.200
US 2003166051	NCL	530/350.000; 424/192.100; 530/300.000
US 2003113838	NCL	435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200
US 2003148371	NCL	435/007.100; 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 514/012.000; 530/388.100; 536/023.200
US 2003190610	NCL	435/325.000; 435/006.000; 435/069.100; 435/252.300; 435/320.100; 530/350.000; 536/023.500
US 2003215904	NCL	435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200
US 2003104469	NCL	435/007.100; 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 530/388.100; 536/023.200
US 2003190611	NCL	435/006.000; 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200
US 2004005553	NCL	435/006.000
US 2002155543	NCL	435/069.400; 435/320.100; 435/325.000; 530/350.000; 536/023.500
JP 2004520810	FTERM	4B024/AA01; 4B024/AA12; 4B024/BA54; 4B024/BA61; 4B024/DA02; 4B024/DA06; 4B024/EA02; 4B024/EA04; 4B024/GA03; 4B024/GA11; 4B024/HA01; 4B024/HA15; 4C076/AA95; 4C076/CC27; 4C076/EE59; 4C076/FF68; 4C084/AA02; 4C084/AA07; 4C084/AA13; 4C084/AA17; 4C084/BA03; 4C084/MA01; 4C084/NA14; 4C084/ZB262; 4C085/AA13; 4C085/AA14; 4C085/AA16; 4C085/BB41; 4C085/CC32; 4C085/DD21; 4C085/EE01; 4C085/GG01; 4C086/AA01; 4C086/AA02; 4C086/AA03; 4C086/AA04; 4C086/CB22; 4C086/EA16; 4C086/MA01; 4C086/MA04; 4C086/NA14; 4C086/ZB26; 4H045/AA11; 4H045/AA30; 4H045/BA10; 4H045/CA41; 4H045/DA76; 4H045/EA28; 4H045/EA51; 4H045/FA74
US 2003207803	NCL	514/012.000; 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 530/388.100; 536/023.200
	ECLA	C07K014/47; C07K014/705
US 2003170254	NCL	424/185.100; 435/069.100; 435/320.100; 435/325.000; 435/183.000; 530/350.000; 530/388.100; 536/023.200
	ECLA	C07K014/705
US 2003199021	NCL	435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200
	ECLA	C07K014/705
US 2003032057	NCL	435/007.100; 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 530/388.100; 536/023.200
US 2003032062	NCL	435/007.100; 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 530/388.100; 536/023.200
US 2003032063	NCL	435/007.100; 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 530/388.100; 536/023.200
US 2003040014	NCL	435/007.100; 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 530/388.100; 536/023.200
US 2003044902	NCL	435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200
US 2003044844	NCL	435/007.100; 435/069.100; 435/320.100; 435/325.000; 435/183.000; 530/350.000; 530/388.100; 536/023.200
JP 2005500030	FTERM	2G045/AA40; 2G045/BB03; 2G045/BB20; 2G045/CB01; 2G045/CB17; 2G045/CB21; 2G045/DA12; 2G045/DA13; 2G045/DA14; 2G045/DA36; 2G045/DA37; 2G045/FB02;

		2G045/FB03; 4B024/AA01; 4B024/AA11; 4B024/BA44; 4B024/BA80; 4B024/CA01; 4B024/CA07; 4B024/DA02; 4B024/DA05; 4B024/DA12; 4B024/GA11; 4B024/HA11; 4B024/HA17; 4B063/QA05; 4B063/QA18; 4B063/QQ79; 4B063/QQ91; 4B063/QR77; 4B063/QR84; 4B063/QS15; 4B063/QX01; 4B064/AG01; 4B064/CA02; 4B064/CA06; 4B064/CA10; 4B064/CC24; 4B064/DA01; 4B065/AA01X; 4B065/AA72X; 4B065/AA91X; 4B065/AA93Y; 4B065/AB01; 4B065/AC14; 4B065/AC20; 4B065/BA02; 4B065/CA24; 4B065/CA25; 4B065/CA44; 4B065/CA46; 4C084/AA02; 4C084/BA01; 4C084/BA02; 4C084/BA08; 4C084/BA19; 4C084/BA20; 4C084/BA22; 4C084/NA14; 4C084/ZA69; 4C084/ZA70; 4C084/ZC21; 4C084/ZC33; 4C084/ZC54; 4H045/AA10; 4H045/AA11; 4H045/BA10; 4H045/CA40; 4H045/DA76; 4H045/EA20; 4H045/EA50; 4H045/FA74
US 2003148438	NCL	435/069.100; 530/350.000; 530/388.100; 536/023.200; 435/183.000; 435/320.100; 435/325.000
	ECLA	C07K014/47
US 2003170788	NCL	435/069.100; 530/350.000; 536/023.200; 435/183.000; 435/320.100; 435/325.000
	ECLA	C07K014/47
US 2003166084	NCL	435/069.100; 530/350.000; 536/023.200; 435/183.000; 435/325.000; 435/320.100
	ECLA	C07K014/47
US 2003134380	NCL	435/069.100; 530/350.000; 536/023.200; 435/183.000; 435/325.000; 435/320.100
	ECLA	C07K014/47
US 2004214269	NCL	435/069.100; 530/350.000; 536/023.200; 435/183.000; 435/320.100; 435/325.000
	ECLA	C07K014/47; C07K014/705
US 2003180875	NCL	435/069.100; 530/350.000; 530/388.100; 536/023.200; 435/183.000; 435/320.100; 435/325.000
	ECLA	C07K014/47; C07K014/705
US 2003199027	NCL	435/069.100; 530/350.000; 530/388.100; 536/023.200; 435/320.100; 435/325.000; 435/183.000
	ECLA	C07K014/47
US 2005074837	NCL	435/069.100; 530/350.000; 530/388.100; 536/023.200; 435/183.000; 435/320.100; 435/325.000
	ECLA	C07K014/47
US 2003068695	NCL	435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200
US 2003068696	NCL	435/069.100; 435/320.100; 435/325.000; 435/183.000; 530/350.000; 536/023.200
US 2003049743	NCL	435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200
US 2003049745	NCL	435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200
US 2003064446	NCL	435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200
US 2003153037	NCL	435/069.100; 435/183.000; 435/325.000; 435/320.100; 530/350.000; 536/023.200
US 2003059879	NCL	435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200
US 2003064448	NCL	435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200
US 2003049747	NCL	435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200
US 2003064449	NCL	435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200
US 2003063112	NCL	345/700.000
US 2003068705	NCL	435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200
US 2003068706	NCL	435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200
US 2003071834	NCL	345/700.000
US 2003049749	NCL	435/069.100; 435/183.000; 435/320.100; 435/325.000;

		530/350.000; 536/023.200
US 2003065159	NCL	536/023.100; 435/320.100; 435/471.000; 435/455.000; 435/483.000; 435/069.100; 530/350.000; 435/069.700; 530/387.100; 435/007.200
US 2003068710	NCL	435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200
US 2003104547	NCL	435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200
US 2003104548	NCL	435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200
US 2003207398	NCL	435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200
US 2003215910	NCL	435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200
US 2003180881	NCL	435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 530/388.100; 536/023.200
US 2003064462	NCL	435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200
US 2003064463	NCL	435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200
US 2003068756	NCL	435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200
US 2003068759	NCL	435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200
US 2003068760	NCL	435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200
US 2003073183	NCL	435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200
US 2003096359	NCL	435/069.100; 435/320.100; 435/325.000; 435/183.000; 530/350.000; 536/023.200
US 2004048334	NCL	435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200
US 2003068765	NCL	435/069.100
US 2003068766	NCL	435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200
US 2003068769	NCL	435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200
US 2003068773	NCL	435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200
US 2003068774	NCL	435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200
US 2003073184	NCL	435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200
US 2003073185	NCL	435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200
US 2003215912	NCL	435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200
US 2004048335	NCL	435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200
US 2003120056	NCL	536/023.500; 435/069.100; 435/320.100; 435/325.000; 530/350.000; 435/252.300; 514/012.000; 530/388.220
	ECLA	A61K047/48R2F; C07K014/515
US 2003144498	NCL	536/023.500; 530/350.000; 435/069.100; 435/320.100; 435/325.000; 530/388.220; 424/143.100; 435/007.200
	ECLA	A61K047/48R2F; C07K014/515
US 2004249141	NCL	536/023.500; 530/350.000; 435/069.100; 435/320.100; 435/325.000
	ECLA	A61K047/48R2F; C07K014/515
US 2003224984	NCL	514/012.000; 530/350.000; 530/388.100; 536/023.200; 435/069.100; 435/183.000; 435/320.100; 435/325.000
	ECLA	C07K014/515; C07K016/22
US 2003199044	NCL	435/069.520; 435/320.100; 435/325.000; 530/351.000; 536/023.500; 424/085.200
US 2004146908	NCL	435/006.000; 435/069.100; 435/320.100; 435/325.000; 530/399.000; 536/023.500
US 2004258710	NCL	424/190.100; 435/069.100; 435/320.100; 435/252.300;

		536/023.700; 530/351.000
	ECLA	C07K014/52A
US 2005009105	NCL	435/007.100
US 2005019823	NCL	435/006.000; 435/069.100; 435/320.100; 435/325.000; 530/350.000; 530/388.100; 536/023.200; 435/183.000
	ECLA	C07K014/47
US 2005153396	NCL	435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 530/388.100; 536/023.200
US 2005153348	NCL	435/006.000; 435/007.230
US 2005164266	NCL	435/006.000; 435/007.100; 435/287.200
US 2005136515	NCL	435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 530/388.100; 536/023.200
	ECLA	C07K014/47
US 2005136475	NCL	435/006.000
	ECLA	C07K014/47; C07K014/705
US 2005158830	NCL	435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 530/388.100; 536/023.200

AB The present invention provides protein and cDNA sequences for human fibroblast growth factor-19 (FGF-19). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide mols. comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Furthermore, methods of treating obesity are provided. It was demonstrated that administration of recombinant FGF-19 leads to increase in food uptake and oxygen consumption, as well as in leptin release from adipocytes in mice. FGF-19 transgenic mice had decreased triglycerides and free fatty acids levels, and decreased glucose uptake by adipocytes. It was also demonstrated, that FGF-19 transgenic mice have improved glucose tolerance and insulin sensitivity. It was shown, that the effects of FGF-19 on the expression of cholesterol-modifying enzymes is FGFR4 dependent, and FGFR4 is not the only functional receptor for FGF-19. Also it was shown, that treatment with FGF-19 reverse diet induced insulin resistance.

ST protein cDNA sequence human FGF19 obesity insulin resistance treatment; human fibroblast growth factor 19 FGFR4 antiobesity antidiabetic

IT Gene, animal
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ACC2, lipogenesis modulating via; protein and cDNA sequences for human fibroblast growth factor-19 (FGF19) and methods of using FGF19 and FGFR4 for treatment of obesity and related disorders)

IT Gene, animal
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(FGFR4, expression modulation; protein and cDNA sequences for human fibroblast growth factor-19 (FGF19) and methods of using FGF19 and FGFR4 for treatment of obesity and related disorders)

IT Gene, animal
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(PPARγ, lipogenesis modulating via; protein and cDNA sequences for human fibroblast growth factor-19 (FGF19) and methods of using FGF19 and FGFR4 for treatment of obesity and related disorders)

IT Drug delivery systems
(carriers; protein and cDNA sequences for human fibroblast growth factor-19 (FGF19) and methods of using FGF19 and FGFR4 for treatment of obesity and related disorders)

IT **Lipids, biological studies**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(lipogenesis, modulating; protein and cDNA sequences for human fibroblast growth factor-19 (FGF19) and methods of using FGF19 and FGFR4 for treatment of obesity and related disorders)

IT Diabetes mellitus
(non-insulin-dependent; protein and cDNA sequences for human fibroblast growth factor-19 (FGF19) and methods of using FGF19 and FGFR4 for

treatment of obesity and related disorders)
IT Antidiabetic agents
Antiobesity agents
Drug design
Drug screening
Gene therapy
Human
Molecular cloning
Obesity
Protein sequences
cDNA sequences
(protein and cDNA sequences for human fibroblast growth factor-19 (FGF19) and methods of using FGF19 and FGFR4 for treatment of obesity and related disorders)
IT Gene, animal
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(scd1, lipogenesis modulating via; protein and cDNA sequences for human fibroblast growth factor-19 (FGF19) and methods of using FGF19 and FGFR4 for treatment of obesity and related disorders)
IT Fibroblast growth factor receptors
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(type 4, modulators; protein and cDNA sequences for human fibroblast growth factor-19 (FGF19) and methods of using FGF19 and FGFR4 for treatment of obesity and related disorders)
IT Peroxisome proliferator-activated receptors
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(γ, PPARγ, lipogenesis modulating via; protein and cDNA sequences for human fibroblast growth factor-19 (FGF19) and methods of using FGF19 and FGFR4 for treatment of obesity and related disorders)
IT 834926-18-0
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; protein and cDNA sequences for human fibroblast growth factor-19 (FGF19) and methods of using FGF19 and FGFR4 for treatment of obesity and related disorders)
IT 9023-93-2, Acetyl-CoA carboxylase
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(gene ACC2, lipogenesis modulating via; protein and cDNA sequences for human fibroblast growth factor-19 (FGF19) and methods of using FGF19 and FGFR4 for treatment of obesity and related disorders)
IT 9014-34-0, Stearoyl-CoA desaturase
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(gene SCD1, lipogenesis modulating via; protein and cDNA sequences for human fibroblast growth factor-19 (FGF19) and methods of using FGF19 and FGFR4 for treatment of obesity and related disorders)
IT 834926-17-9
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nucleotide sequence; protein and cDNA sequences for human fibroblast growth factor-19 (FGF19) and methods of using FGF19 and FGFR4 for treatment of obesity and related disorders)
IT 186287-16-1, GENBANK AA220994 194445-81-3, GENBANK AF007268
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(protein and cDNA sequences for human fibroblast growth factor-19 (FGF19) and methods of using FGF19 and FGFR4 for treatment of obesity and related disorders)
IT 223121-69-5, Fibroblast growth factor 19
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(protein and cDNA sequences for human fibroblast growth factor-19

(FGF19) and methods of using FGF19 and FGFR4 for treatment of obesity and related disorders)

IT 9004-10-8, Insulin, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(resistance, preventing; protein and cDNA sequences for human fibroblast growth factor-19 (FGF19) and methods of using FGF19 and FGFR4 for treatment of obesity and related disorders)

IT 834928-80-2 834928-81-3 834928-82-4 834928-83-5 834928-84-6
834928-85-7 834928-86-8 834928-87-9 834928-88-0 834928-89-1
834928-90-4 834928-91-5 834928-92-6 834928-93-7 834928-94-8
834928-95-9 834928-96-0 834928-97-1
RL: PRP (Properties)
(unclaimed nucleotide sequence; protein and cDNA sequences for human fibroblast growth factor-19 (FGF19) and methods of using FGF19 and FGFR4 for the treatment of obesity and related disorders)

L45 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:101274 HCAPLUS
DN 140:158645
ED Entered STN: 08 Feb 2004
TI Genes overexpressed in adipocytes and their use in diagnosis and treatment of adipose tissue disorders
IN Chada, Kiran; Chouinard, Roland; Ashar, Hena; Sayed, Abu M. D.
PA Hmgene, Inc., USA
SO PCT Int. Appl., 91 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C12N
CC 3-3 (Biochemical Genetics)
Section cross-reference(s): 1, 9, 14
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004011618	A2	20040205	WO 2003-US23684	20030729

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2002-398785P P 20020729
US 2003-478206P P 20030612

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004011618	ICM	C12N
WO 2004011618	ECLA	C07K014/47; C07K014/72; C12N009/00; C12Q001/68M6

AB Disclosed is a method of identifying genes that are over-expressed in adipose tissue as compared to pre-adipocyte tissue or other tissues, comprising performing differential gene expression anal. between the white adipose tissue (WAT) or stromal vascular tissue (SVT) from any two different mice selected from the group consisting of wild-type, HMGI-C -/-, ob/ob, and HMGI-C-/- ob/ob genotype mice. Based on this differential gene expression anal. using the Affymetrix GeneChip MG-U74, a number of nucleotide sequences are identified whose expression is adipocyte-specific. A preferred embodiment of the invention is expression of the sFRP-5 (secreted frizzled-related protein 5) and npr-3 (natriuretic peptide receptor C) genes. The identified nucleotide sequences and their corresponding polypeptides may then be used to **prevent** adipogenesis, to treat diabetes, and to screen for small mols. that can **modulate** or **prevent** adipogenesis and to treat diabetes

and obesity.
ST gene expression profile adipocyte diagnosis therapy; adipose tissue disorder diagnosis therapy gene expression; sequence adipocyte specific cDNA protein mouse human
IT Syntaxins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(1B, -like mol.; genes overexpressed in adipocytes and their use in diagnosis and treatment of adipose tissue disorders)
IT DNA microarray technology
Gene expression profiles, animal
(Affymetrix MG-U74 GeneChip; genes overexpressed in adipocytes and their use in diagnosis and treatment of adipose tissue disorders)
IT Proteins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Arl4; genes overexpressed in adipocytes and their use in diagnosis and treatment of adipose tissue disorders)
IT Chemokines
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CCL17 (C-C motif ligand 17); genes overexpressed in adipocytes and their use in diagnosis and treatment of adipose tissue disorders)
IT Chemokine receptors
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CCR2; genes overexpressed in adipocytes and their use in diagnosis and treatment of adipose tissue disorders)
IT Chemokine receptors
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CCR6; genes overexpressed in adipocytes and their use in diagnosis and treatment of adipose tissue disorders)
IT Antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CD1d1; genes overexpressed in adipocytes and their use in diagnosis and treatment of adipose tissue disorders)
IT CD antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CD53; genes overexpressed in adipocytes and their use in diagnosis and treatment of adipose tissue disorders)
IT Proteins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(FSP27; genes overexpressed in adipocytes and their use in diagnosis and treatment of adipose tissue disorders)
IT G protein-coupled receptors
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(GPR127; genes overexpressed in adipocytes and their use in diagnosis and treatment of adipose tissue disorders)
IT G protein-coupled receptors
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(GPR18; genes overexpressed in adipocytes and their use in diagnosis and treatment of adipose tissue disorders)
IT G proteins (guanine nucleotide-binding proteins)
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Gi (adenylate cyclase-**inhibiting**), α1-subunit; genes overexpressed in adipocytes and their use in diagnosis and treatment of adipose tissue disorders)
IT G proteins (guanine nucleotide-binding proteins)
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP

(Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(G2; genes overexpressed in adipocytes and their use in diagnosis and treatment of adipose tissue disorders)

IT Transcription factors
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(IRF-4 (interferon regulatory factor 4); genes overexpressed in adipocytes and their use in diagnosis and treatment of adipose tissue disorders)

IT Proteins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Isg12; genes overexpressed in adipocytes and their use in diagnosis and treatment of adipose tissue disorders)

IT Transcription factors
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(KLF5 (Kruppel-like factor 5); genes overexpressed in adipocytes and their use in diagnosis and treatment of adipose tissue disorders)

IT Proteins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(LBH (limb-bud and heart gene); genes overexpressed in adipocytes and their use in diagnosis and treatment of adipose tissue disorders)

IT Cyclins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(M-3; genes overexpressed in adipocytes and their use in diagnosis and treatment of adipose tissue disorders)

IT Proteins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Peg1/MEST; genes overexpressed in adipocytes and their use in diagnosis and treatment of adipose tissue disorders)

IT Proteins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(RELMα (resistin-like mol. α); genes overexpressed in adipocytes and their use in diagnosis and treatment of adipose tissue disorders)

IT Proteins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Ras protein p21ras activator 2; genes overexpressed in adipocytes and their use in diagnosis and treatment of adipose tissue disorders)

IT Proteins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Ras-like GTPase TC10; genes overexpressed in adipocytes and their use in diagnosis and treatment of adipose tissue disorders)

IT Proteins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(S3-12; genes overexpressed in adipocytes and their use in diagnosis and treatment of adipose tissue disorders)

IT Proteins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Vap-1; genes overexpressed in adipocytes and their use in diagnosis and treatment of adipose tissue disorders)

IT **Adipose tissue**
(adipocyte; genes overexpressed in adipocytes and their use in diagnosis and treatment of adipose tissue disorders)

IT Calcium-binding proteins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(calgranulin B; genes overexpressed in adipocytes and their use in diagnosis and treatment of adipose tissue disorders)

IT Proteins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(copine II; genes overexpressed in adipocytes and their use in diagnosis and treatment of adipose tissue disorders)

IT Proteins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coronin; genes overexpressed in adipocytes and their use in diagnosis and treatment of adipose tissue disorders)

IT Proteins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(decay accelerating factor 1; genes overexpressed in adipocytes and their use in diagnosis and treatment of adipose tissue disorders)

IT Susceptibility (genetic)
(diagnosis of; genes overexpressed in adipocytes and their use in diagnosis and treatment of adipose tissue disorders)

IT Transcription factors
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(early B-cell factor; genes overexpressed in adipocytes and their use in diagnosis and treatment of adipose tissue disorders)

IT Bioassay
(for agents **preventing** adipose accumulation; genes overexpressed in adipocytes and their use in diagnosis and treatment of adipose tissue disorders)

IT High throughput screening
(for **modulating** agents; genes overexpressed in adipocytes and their use in diagnosis and treatment of adipose tissue disorders)

IT Agglutinins and Lectins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(galectin 12; genes overexpressed in adipocytes and their use in diagnosis and treatment of adipose tissue disorders)

IT G proteins (guanine nucleotide-binding proteins)
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(gene CDC42; genes overexpressed in adipocytes and their use in diagnosis and treatment of adipose tissue disorders)

IT **Adipose tissue**
Angiogenesis
Antidiabetic agents
Antiobesity agents
Diabetes mellitus
Drug screening
Human
Mus
Obesity
Protein sequences
Rattus
cDNA sequences
(genes overexpressed in adipocytes and their use in diagnosis and treatment of adipose tissue disorders)

IT Lactoferrins
RANTES (chemokine)
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(genes overexpressed in adipocytes and their use in diagnosis and treatment of adipose tissue disorders)

IT Diagnosis
(mol.; genes overexpressed in adipocytes and their use in diagnosis and treatment of adipose tissue disorders)

IT Antibodies and Immunoglobulins

RL: DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(monoclonal; genes overexpressed in adipocytes and their use in diagnosis and treatment of adipose tissue disorders)

IT Proteins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(neuronatin; genes overexpressed in adipocytes and their use in diagnosis and treatment of adipose tissue disorders)

IT **Adipose tissue**
(preadipocyte; genes overexpressed in adipocytes and their use in diagnosis and treatment of adipose tissue disorders)

IT Proteins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(retinol-binding, 4; genes overexpressed in adipocytes and their use in diagnosis and treatment of adipose tissue disorders)

IT Hedgehog protein
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sonic; genes overexpressed in adipocytes and their use in diagnosis and treatment of adipose tissue disorders)

IT Proteins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(thyroid hormone-responsive SPOT14; genes overexpressed in adipocytes and their use in diagnosis and treatment of adipose tissue disorders)

IT G proteins (guanine nucleotide-binding proteins)
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(α2-subunit; genes overexpressed in adipocytes and their use in diagnosis and treatment of adipose tissue disorders)

IT 78169-47-8, Aspartic proteinase
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(-like protein; genes overexpressed in adipocytes and their use in diagnosis and treatment of adipose tissue disorders)

IT **9001-03-0**
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(II; genes overexpressed in adipocytes and their use in diagnosis and treatment of adipose tissue disorders)

IT 654291-03-9 654291-04-0 654291-05-1 654291-06-2 654291-07-3
654291-08-4 654291-09-5 654291-10-8 654291-11-9 654291-12-0
654291-13-1 654291-14-2 654291-15-3 654291-16-4 654291-17-5
654291-18-6 654291-19-7 654291-20-0 654291-21-1 654291-22-2
654291-23-3 654291-24-4 654291-25-5 654291-26-6 654291-27-7
654291-28-8 654291-29-9 654291-30-2 654291-31-3 654291-32-4
654291-33-5 654291-34-6 654291-35-7 654291-36-8 654291-37-9
654291-38-0 654291-39-1 654291-40-4 654291-41-5 654291-42-6
654291-43-7 654291-44-8 654291-45-9 654291-46-0 654291-47-1
654291-48-2 654291-49-3 654291-50-6 654291-51-7 654291-52-8
654291-53-9 654291-54-0 654291-55-1 654291-56-2 654291-57-3
654291-58-4 654291-59-5 654291-60-8 654291-61-9 654291-62-0
654291-63-1 654291-64-2 654291-65-3 654291-66-4 654291-67-5
654291-68-6 654291-69-7 654291-70-0 654291-71-1 654291-72-2
654291-73-3 654291-74-4 654291-75-5 654291-76-6 654291-77-7
654291-78-8 654291-79-9
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; genes overexpressed in adipocytes and their use in diagnosis and treatment of adipose tissue disorders)

IT 9001-99-4, RNase
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(eosinophil-associated 1; genes overexpressed in adipocytes and their use

in diagnosis and treatment of adipose tissue disorders)

IT 9003-99-0, Myeloperoxidase 79747-53-8, Protein tyrosine phosphatase
90698-32-1, Leukotriene C4 synthase 128028-50-2, Proteinase 3
146480-36-6, Matrix metalloproteinase 9 216864-09-4, SYnuclein γ
503473-02-7, Nitric oxide synthase 3
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(genes overexpressed in adipocytes and their use in diagnosis and treatment of adipose tissue disorders)

IT 654288-30-9 654288-31-0 654288-32-1 654288-33-2 654288-34-3
654288-35-4 654288-36-5 654288-37-6 654288-38-7 654288-39-8
654288-40-1 654288-41-2 654288-42-3 654288-43-4 654288-44-5
654288-45-6 654288-46-7 654288-47-8 654288-48-9 654288-49-0
654288-50-3 654288-51-4 654288-52-5 654288-53-6 654288-54-7
654288-55-8 654288-56-9 654288-57-0 654288-58-1 654288-59-2
654288-60-5 654288-61-6 654288-62-7 654288-63-8 654288-64-9
654288-65-0 654288-66-1 654288-67-2 654288-68-3 654288-69-4
654288-70-7 654288-71-8 654288-72-9 654288-73-0 654288-74-1
654288-75-2 654288-76-3 654288-77-4 654288-78-5 654288-79-6
654288-80-9 654288-81-0 654288-82-1 654288-83-2 654288-84-3
654288-85-4 654288-86-5 654288-87-6 654288-88-7 654288-89-8
654288-90-1 654288-91-2 654288-92-3 654288-93-4 654288-94-5
654288-95-6 654288-96-7 654288-97-8 654288-98-9 654288-99-0
654289-00-6 654289-01-7 654289-02-8 654289-03-9 654289-04-0
654289-05-1 654289-06-2 654289-07-3 654289-08-4 654289-09-5
654289-10-8 654289-11-9 654289-12-0 654289-13-1 654289-14-2
654289-15-3 **654289-16-4** **654289-17-5** 654289-18-6
654289-19-7 654289-20-0 654289-21-1 654289-22-2 654289-23-3
654289-24-4 654289-25-5 654289-26-6 654289-27-7 654289-28-8
654289-29-9 654289-30-2 654289-31-3 654289-32-4 654289-33-5
654289-34-6 654289-35-7 654289-36-8 654289-37-9 654289-38-0
654289-39-1 654289-40-4 654289-41-5 654289-42-6 654289-43-7
654289-44-8 654289-45-9 654289-46-0 654289-47-1 654289-48-2
654289-49-3 654289-50-6 654289-51-7 654289-52-8 654289-53-9
654289-54-0 654289-55-1 654289-56-2 654289-57-3 654289-58-4
654289-59-5 654289-60-8 654289-61-9 654289-62-0 654289-63-1
654289-64-2 654289-65-3 654289-66-4 654289-67-5 654289-68-6
654289-69-7 654289-70-0 654289-71-1 654289-72-2 654289-73-3
654289-74-4 654289-75-5 654289-76-6 654289-77-7 654289-78-8
654289-79-9 654289-80-2 654289-81-3 654289-82-4 654289-83-5
654289-84-6 654289-85-7 654289-86-8 654289-87-9 654289-88-0
654289-89-1 654289-90-4 654289-91-5 654289-92-6 654289-93-7
654289-94-8 654289-95-9 654289-96-0 654289-97-1 654289-98-2
654289-99-3 654290-00-3 654290-01-4 654290-02-5 654290-03-6
654290-04-7 654290-05-8 654290-06-9 654290-07-0 654290-08-1
654290-09-2 654290-10-5 654290-11-6 654290-12-7 654290-13-8
654290-14-9 654290-15-0 654290-16-1 654290-17-2 654290-18-3
654290-19-4 654290-20-7 654290-21-8 654290-22-9 654290-23-0
654290-24-1 654290-25-2 654290-26-3 654290-27-4 654290-28-5
654290-29-6 654290-30-9 654290-31-0 654290-32-1 654290-33-2
654290-34-3 654290-35-4 654290-36-5 654290-37-6 654290-38-7
654290-39-8 654290-40-1 654290-41-2 654290-42-3 654290-43-4
654290-44-5 654290-45-6 654290-46-7 654290-47-8 654290-48-9
654290-49-0 654290-50-3 654290-51-4 654290-52-5 654290-53-6
654290-54-7 654290-55-8 654290-56-9 654290-57-0 654290-58-1
654290-59-2 654290-60-5 654290-61-6 654290-62-7 654290-63-8
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nucleotide sequence; genes overexpressed in adipocytes and their use in diagnosis and treatment of adipose tissue disorders)

IT 654290-64-9 654290-65-0 654290-66-1 654290-67-2 654290-68-3
654290-69-4 654290-70-7 654290-71-8 654290-72-9 654290-73-0
654290-74-1 654290-75-2 654290-76-3 654290-77-4 654290-78-5
654290-79-6 654290-80-9 654290-81-0 654290-82-1 654290-83-2
654290-84-3 654290-85-4 654290-86-5 654290-87-6 654290-88-7
654290-89-8 654290-90-1 654290-91-2 654290-92-3 654290-93-4

654290-94-5 654290-95-6 654290-96-7 654290-97-8 654290-98-9
654290-99-0 654291-00-6 654291-01-7 654291-02-8
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nucleotide sequence; genes overexpressed in adipocytes and their use in diagnosis and treatment of adipose tissue disorders)

IT 9016-18-6, Carboxylesterase
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(p62/CE; genes overexpressed in adipocytes and their use in diagnosis and treatment of adipose tissue disorders)

IT 140879-24-9, Proteasome
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(subunit β5; genes overexpressed in adipocytes and their use in diagnosis and treatment of adipose tissue disorders)

IT 654306-82-8 654306-83-9 654306-84-0 654306-85-1 654306-86-2
654306-87-3 654306-88-4 654306-89-5 654306-90-8 654306-91-9
654306-92-0
RL: PRP (Properties)
(unclaimed protein sequence; genes overexpressed in adipocytes and their use in diagnosis and treatment of adipose tissue disorders)

IT **9001-03-0**
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(II; genes overexpressed in adipocytes and their use in diagnosis and treatment of adipose tissue disorders)

RN 9001-03-0 HCAPLUS
CN Dehydratase, carbonate (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **654289-16-4 654289-17-5**
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nucleotide sequence; genes overexpressed in adipocytes and their use in diagnosis and treatment of adipose tissue disorders)

RN 654289-16-4 HCAPLUS
CN DNA (rat clone WO2004011618-SEQID-89 carbonate dehydratase isoenzyme II cDNA plus flanks) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 654289-17-5 HCAPLUS
CN DNA (rat clone WO2004011618-SEQID-90 carbonate dehydratase isoenzyme II cDNA plus flanks) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L45 ANSWER 3 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN
AN **2003:511950** HCAPLUS
DN 139:79155
ED Entered STN: 04 Jul 2003
TI Carbohydrate response element-binding protein and uses thereof
IN Uyeda, Kosaku
PA USA
SO U.S. Pat. Appl. Publ., 64 pp.
CODEN: USXXCO
DT Patent
LA English
IC ICM A61K031-00
ICS C12Q001-68
INCL 435006000; 514001000
CC 1-10 (Pharmacology)
Section cross-reference(s): 3
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI US 2003124590 A1 20030703 US 2002-272206 20021016
PRAI US 2001-329834P P 20011016
CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2003124590	ICM	A61K031-00
	ICS	C12Q001-68
	INCL	435006000; 514001000
US 2003124590	NCL	435/006.000; 514/001.000
	ECLA	A61K031/00

AB The present invention relates to the field of transcriptional regulation. More specifically, it relates to a novel transcription factor, Carbohydrate Response Element-Binding Protein (ChREBP). ChREBP is associated with carbohydrate metabolism and the conversion of dietary excess carbohydrate to body fat. The present invention relates to activation and inhibition of ChREBP transcriptional activity and uses thereof.

ST carbohydrate response element binding protein lipogenesis

IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ChREBP (carbohydrate response element-binding protein); carbohydrate response element-binding protein for antiobesity and antidiabetic use)

IT Cell nucleus
(ChREBP localization into; carbohydrate response element-binding protein for antiobesity and antidiabetic use)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(DNA-binding, modulators of; carbohydrate response element-binding protein for antiobesity and antidiabetic use)

IT Signal peptides
(NLS (nuclear localization signal); carbohydrate response element-binding protein for antiobesity and antidiabetic use)

IT Antidiabetic agents
Antiobesity agents
Blood vessel, disease
Cardiovascular agents
Diabetes mellitus
Drug screening
Human
Liver
Metabolic pathways
Molecular cloning
Obesity
(carbohydrate response element-binding protein for antiobesity and antidiabetic use)

IT Enzymes, biological studies
Hormones, animal, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(carbohydrate response element-binding protein for antiobesity and antidiabetic use)

IT Genetic element
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(carbohydrate response element; carbohydrate response element-binding protein for antiobesity and antidiabetic use)

IT Diet
(high-carbohydrate; carbohydrate response element-binding protein for antiobesity and antidiabetic use)

IT Glycolysis
(inhibition of; carbohydrate response element-binding protein for antiobesity and antidiabetic use)

IT **Lipids, biological studies**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(lipogenesis, inhibition of; carbohydrate response element-binding protein for antiobesity and antidiabetic use)

IT Phosphorylation, biological
(modulators of; carbohydrate response element-binding protein for antiobesity and antidiabetic use)

IT Carbohydrates, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(response element; carbohydrate response element-binding protein for antiobesity and antidiabetic use)
IT Liver
(toxicity; carbohydrate response element-binding protein for antiobesity and antidiabetic use)
IT 9004-10-8, Insulin, biological studies 9023-93-2, Acetyl coa carboxylase
9027-95-6, Atp citrate lyase 9045-77-6, Fatty acid synthase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(DNA encoding; carbohydrate response element-binding protein for antiobesity and antidiabetic use)
IT 9001-59-6, Pyruvate kinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(L-type, DNA encoding; carbohydrate response element-binding protein for antiobesity and antidiabetic use)
IT 552442-96-3 552442-97-4 552442-98-5
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; carbohydrate response element-binding protein for antiobesity and antidiabetic use)
IT 362-74-3, Dibutyryl-camp
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(carbohydrate response element-binding protein for antiobesity and antidiabetic use)
IT 9013-05-2, Phosphatase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; carbohydrate response element-binding protein for antiobesity and antidiabetic use)
IT 9014-00-0, Luciferase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(marker gene encoding; carbohydrate response element-binding protein for antiobesity and antidiabetic use)
IT 50-99-7, Glucose, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(metabolism of; carbohydrate response element-binding protein for antiobesity and antidiabetic use)
IT 552444-25-4 552444-26-5 552444-27-6 552444-28-7 552444-29-8
552444-30-1 552444-31-2 552444-32-3 552444-33-4 552444-34-5
552444-35-6 552444-36-7 552444-37-8 552444-38-9 552444-39-0
552444-40-3 552444-41-4 552444-42-5 552444-43-6 552444-44-7
552444-45-8 552444-46-9 552444-47-0 552444-48-1 552444-49-2
552444-50-5 552444-51-6 552444-52-7 552444-53-8 552444-54-9
552444-55-0 552444-56-1 552444-57-2 552444-58-3 552444-59-4
552444-60-7 552444-61-8 552444-62-9 552444-63-0 552444-64-1
552444-65-2 552444-66-3 552444-67-4 552444-68-5 552444-69-6
552444-70-9 552444-71-0 552444-72-1 552444-73-2 552444-74-3
552444-75-4 552444-76-5 552444-77-6 552444-78-7 552444-79-8
552444-80-1 552444-81-2 552444-82-3 552444-83-4 552444-84-5
552444-85-6 552444-86-7
RL: PRP (Properties)
(unclaimed nucleotide sequence; carbohydrate response element-binding protein and uses thereof)
IT 125911-68-4 552315-06-7 552315-07-8 552315-08-9
RL: PRP (Properties)
(unclaimed sequence; carbohydrate response element-binding protein and uses thereof)

L45 ANSWER 4 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN
AN **2003:511096** HCAPLUS
DN 139:81326
ED Entered STN: 04 Jul 2003
TI Human and mouse diacylglycerol acyltransferase 2 sequence homologs, their sequences, recombinant production, and use as modulators in treatment of disorders such as obesity

IN Gimeno, Ruth E.; Wu, Zhidan; Kapeller-Libermann, Rosana; Hubbard, Brian K.
PA Millennium Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 154 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K
CC 7-5 (Enzymes)
Section cross-reference(s): 1, 3, 13, 14

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003053363	A2	20030703	WO 2002-US40974	20021219
WO 2003053363	A3	20040429		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003170691	A1	20030911	US 2002-324618	20021219
EP 1455815	A2	20040915	EP 2002-805653	20021219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
PRAI US 2001-341947P	P	20011219		
US 2002-411859P	P	20020919		
WO 2002-US40974	W	20021219		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2003053363	ICM	A61K
WO 2003053363	ECLA	C12N009/10C1A
US 2003170691	NCL	435/006.000; 435/069.100; 435/193.000; 435/320.100; 435/325.000; 536/023.200
	ECLA	C12N009/10C1A

AB The invention provides various cDNA mols. encoding human and mouse diacylglycerol acyltransferase 2 (DGAT2) sequence homologs. The human cDNA mols. are designated 60489, 112041, 112037, 58765, 58765short, 112023, 112024 and hDC2, while the mouse cDNA mols. are designated m86606, m5875, m112023, and mDC2. The invention also provides a vector containing said cDNA mols., and a host cell transformed with said vector for recombinant DGAT2 sequence homolog protein production The invention further provides said DGAT2 sequence homolog polypeptides, and antibodies, and/or fusion proteins thereof. Still further, the invention provides a method for: (a) identifying a compound capable of modulating an adipocyte activity using said DGAT2 family member cDNA mols. or polypeptides, and use of identified modulator; (b) determining acyltransferase activity of a polypeptide (such as DGAT2 sequence homologs) utilizing labeled substrates; and (c) identifying a compound (modulator) capable of treating a disorder characterized by aberrant DGAT2 family member nucleic acid expression or activity (such as obesity), wherein said modulator is organic small mol., and anti-DGAT2 antibody, or one of the disclosed DGAT2 sequence homolog polypeptides. Finally, the invention provides the cDNA and amino acid sequences of said human and mouse DGAT2 sequence homologs. The invention discussed that the DGAT2 sequence homologs can be used in screening assays, and as therapeutic agents for controlling one or more disorders associated with adipocyte differentiation and metabolism, and metabolic disorders. The invention is based, at least in part, on the discovery that the DGAT2 sequence homolog cDNAs and polypeptides were expressed at high levels in adipose, liver and small intestine, colon, and kidney, and were regulated during conditions which affect differentiation and metabolism of adipocytes, and are downregulated in genetic animal models of obesity.

ST cDNA diacylglycerol acyltransferase 2 sequence homolog human mouse; protein sequence diacylglycerol acyltransferase 2 homolog human mouse; recombinant prodn diacylglycerol acyltransferase 2 sequence homolog; therapy obesity aberrant lipogenesis anti DGAT2 antibody small mol; obesity aberrant lipogenesis therapy DGAT2 sequence homolog; triglyceride aberrant synthesis treatment DGAT2 sequence homolog

IT **Lipids, biological studies**
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(aberrant generation of; method for identifying compound capable of treating disorder associated with aberrant DGAT2 family member, wherein said disorder is associated with obesity, aberrant lipogenesis or triglyceride synthesis)

IT **Glycerides, biological studies**
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(aberrant synthesis of; method for identifying compound capable of treating disorder associated with aberrant DGAT2 family member, wherein said disorder is associated with obesity, aberrant lipogenesis or triglyceride synthesis)

IT Adipose tissue
(adipocyte; modulating adipocyte activity (such as diacylglyceroltransferase activity, hyperplastic growth, hypertropic growth or lipogenesis) using DGAT2 sequence homologs, anti-DGAT2 antibodies or organic small mol.)

IT Antibodies and Immunoglobulins
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antibodies specific for human and mouse diacylglycerol acyltransferase 2 sequence homologs, and use of anti-DGAT2 antibodies as modulator for treating individual suffering with obesity, aberrant lipogenesis or triglyceride synthesis)

IT Diglycerides
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(as substrate, labeled with biotin or radioactivity; method use for determining acyltransferase activity of human and mouse DGAT2 sequence homologs using labeled fatty acyl CoA and acylglyceride substrates)

IT Molecular cloning
(cDNA mols. encoding human and mouse diacylglycerol acyltransferase 2 (DGAT2) sequence homologs, and plasmid vectors containing said cDNAs for use in recombinant protein production)

IT cDNA sequences
(cDNA mols. encoding human and mouse diacylglycerol acyltransferase 2 sequence homologs, their sequences, and biol. uses)

IT Fusion proteins (chimeric proteins)
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(human and mouse diacylglycerol acyltransferase 2 sequence homologs, and fusion proteins comprising said homologs)

IT Human
(human diacylglycerol acyltransferase 2 sequence homologs, their sequences, recombinant production, and use as modulators in treatment of disorders such as obesity)

IT **Lipids, biological studies**
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(metabolic disorders; method for identifying compound capable of treating disorder associated with aberrant DGAT2 family member, wherein said disorder is associated with obesity, aberrant lipogenesis or triglyceride synthesis)

IT Antiobesity agents
Drug screening
Obesity
(method for identifying compound capable of treating disorder associated with aberrant DGAT2 family member, wherein said disorder is associated with obesity, aberrant lipogenesis or triglyceride synthesis)

IT Protein sequences
(mouse and human diacylglycerol acyltransferase 2 sequence homologs, their sequences, recombinant production, and use as modulators in treatment of disorders such as obesity)

IT Mus musculus
(mouse diacylglycerol acyltransferase 2 sequence homologs, their sequences, recombinant production, and use as modulators in treatment of disorders such as obesity)

IT 9029-98-5P, Diacylglycerol acyltransferase
RL: BPN (Biosynthetic preparation); BUU (Biological use, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(2, sequence homolog; human and mouse diacylglycerol acyltransferase 2 sequence homologs, their sequences, recombinant production, and use as modulators of adipocyte activity and in treatment of disorders such as obesity)

IT 552443-59-1P 552443-61-5P 552443-63-7P 552443-65-9P 552443-68-2P
552443-70-6P 552443-72-8P 552443-74-0P 552443-76-2P
RL: BPN (Biosynthetic preparation); BUU (Biological use, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; human and mouse diacylglycerol acyltransferase 2 sequence homologs, their sequences, recombinant production, and use as modulators of adipocyte activity and in treatment of disorders such as obesity)

IT 552443-79-5P
RL: BPN (Biosynthetic preparation); BUU (Biological use, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; human and mouse diacylglycerol acyltransferase 2 sequence homologs, their uses and use as modulators in treatment of disorders such as obesity)

IT 552443-80-8 552443-81-9
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; human and mouse diacylglycerol acyltransferase 2 sequence homologs, their uses as modulators in treatment of disorders such as obesity)

IT 552443-29-5
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; of human diacylglycerol acyltransferase 2, and its use as a modulator in treatment of disorders such as obesity)

IT 85-61-0D, Coenzyme A, fatty acyl derivs., labeled with biotin or radioactivity
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(as substrate; method use for determining acyltransferase activity of human and mouse DGAT2 sequence homologs using labeled fatty acyl CoA and acylglyceride substrates)

IT 9055-17-8, Monoacylglycerol acyltransferase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(method use for determining acyltransferase activity of human and mouse DGAT2 sequence homologs using labeled fatty acyl CoA and acylglyceride substrates)

IT 552443-57-9 552443-58-0 552443-60-4 552443-62-6 552443-64-8
552443-66-0 552443-67-1 552443-69-3 552443-71-7 552443-73-9
552443-75-1 552443-77-3 552443-78-4
RL: BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)
(nucleotide sequence; cDNA mols. encoding human and mouse diacylglycerol acyltransferase 2 sequence homologs, their sequences, and biol. uses)

IT 552444-94-7 552444-95-8 552444-96-9 552444-97-0 552444-98-1
552444-99-2 552445-00-8 552445-01-9 552445-02-0 552445-03-1
552445-04-2 552445-05-3 552445-06-4 552445-07-5 552445-08-6
552445-09-7 552445-10-0 552445-11-1 552445-12-2 552445-13-3
552445-14-4 552445-15-5 552445-16-6 552445-17-7 552445-18-8
552445-19-9 552445-20-2 552445-21-3 552445-22-4 552445-23-5
552445-24-6 552445-25-7 552445-26-8 552445-27-9 552445-28-0
552445-29-1 552445-30-4 552445-31-5 552445-32-6

RL: PRP (Properties)
(unclaimed nucleotide sequence; human and mouse diacylglycerol acyltransferase 2 sequence homologs, their sequences, recombinant production, and use as modulators in treatment of disorders such as obesity)

L45 ANSWER 5 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN
AN **2002:736796** HCAPLUS
DN 137:257694
ED Entered STN: 27 Sep 2002
TI Short peptides from the 'A-region' of protein kinases which selectively modulate protein kinase activity
IN Ben-Sasson, Shmuel
PA Children's Medical Center Corporation, USA
SO U.S. Pat. Appl. Publ., 79 pp., Cont.-in-part of U.S. Ser. No. 734,520.
CODEN: USXXCO
DT Patent
LA English
IC ICM C12Q001-68
ICS C12N009-12; A61K038-16; C12P021-02
INCL 435069100
CC 1-12 (Pharmacology)
Section cross-reference(s): 7
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2002137141	A1	20020926	US 2001-12034	20011211
US 2002115173	A1	20020822	US 2000-734520	20001211
PRAI US 2000-734520	A2	20001211		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2002137141	ICM	C12Q001-68
	ICS	C12N009-12; A61K038-16; C12P021-02
	INCL	435069100
US 2002137141	NCL	435/069.100; 514/012.000; 435/006.000; 435/194.000
	ECLA	C12N009/12B1
US 2002115173	NCL	435/194.000; 435/070.210; 435/007.920
	ECLA	C12N009/12B1

OS MARPAT 137:257694
AB The invention provides compds. comprising, within short sequences from a specific region of the kinase, that can modulate kinase-associated signal transduction. Methods for identification of candidate compds. are disclosed, as are disease treatment methods.
ST protein kinase peptide screening signal transduction therapeutic
IT Protein motifs
(A region; peptides from A-region of protein kinases which selectively modulate protein kinase activity)
IT Adipose tissue
(adipocyte, lipogenesis; peptides from A-region of protein kinases which selectively modulate protein kinase activity)
IT **Lipids, biological studies**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(adipose cell lipogenesis; peptides from A-region of protein kinases which selectively modulate protein kinase activity)
IT Antiarteriosclerotics
(antiatherosclerotics; peptides from A-region of protein kinases which selectively modulate protein kinase activity)
IT Nervous system, disease
(central; peptides from A-region of protein kinases which selectively modulate protein kinase activity)
IT Nervous system, disease
(degeneration; peptides from A-region of protein kinases which selectively modulate protein kinase activity)
IT Immunity
(disorder; peptides from A-region of protein kinases which selectively

modulate protein kinase activity)
IT Biological transport
(drug; peptides from A-region of protein kinases which selectively modulate protein kinase activity)
IT Blood vessel
(endothelium, protein kinase; peptides from A-region of protein kinases which selectively modulate protein kinase activity)
IT Blood
(glucose level; peptides from A-region of protein kinases which selectively modulate protein kinase activity)
IT Bone
(healing; peptides from A-region of protein kinases which selectively modulate protein kinase activity)
IT Neoplasm
(metastasis; peptides from A-region of protein kinases which selectively modulate protein kinase activity)
IT Nervous system
(neural crest, neural crest cell emigration; peptides from A-region of protein kinases which selectively modulate protein kinase activity)
IT Axon
(outgrowth; peptides from A-region of protein kinases which selectively modulate protein kinase activity)
IT Adipose tissue
Alopecia
Anti-inflammatory agents
Antidiabetic agents
Antiobesity agents
Antitumor agents
Appetite
Atherosclerosis
Autoimmune disease
Body weight
Cardiovascular agents
Cardiovascular system, disease
Cell proliferation
Diabetes mellitus
Drug delivery systems
Drug screening
Fibrosis
Infection
Inflammation
Metabolism
Neoplasm
Nervous system agents
Obesity
Osteoporosis
Peptidomimetics
Secretion (process)
Signal transduction, biological
Skin, disease
(peptides from A-region of protein kinases which selectively modulate protein kinase activity)
IT Cytokines
Hormones, animal, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(peptides from A-region of protein kinases which selectively modulate protein kinase activity)
IT Peptides, biological studies
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptides from A-region of protein kinases which selectively modulate protein kinase activity)
IT Phosphorylation, biological
(protein; peptides from A-region of protein kinases which selectively modulate protein kinase activity)
IT Animal tissue

(remodeling; peptides from A-region of protein kinases which selectively modulate protein kinase activity)

IT Artery, disease
(restenosis; peptides from A-region of protein kinases which selectively modulate protein kinase activity)

IT Neurotrophic factor receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ret; peptides from A-region of protein kinases which selectively modulate protein kinase activity)

IT Wound
(scar formation; peptides from A-region of protein kinases which selectively modulate protein kinase activity)

IT Animal cell
(shape and elongation; peptides from A-region of protein kinases which selectively modulate protein kinase activity)

IT Biological transport
(uptake, glucose; peptides from A-region of protein kinases which selectively modulate protein kinase activity)

IT Endothelium
(vascular, protein kinase; peptides from A-region of protein kinases which selectively modulate protein kinase activity)

IT Amino acids, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(D-; peptides from A-region of protein kinases which selectively modulate protein kinase activity)

IT 142008-29-5, Protein kinase A
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Cα; peptides from A-region of protein kinases which selectively modulate protein kinase activity)

IT 438582-72-0 438582-73-1 438582-74-2 438582-75-3 438582-76-4
438582-77-5 438582-79-7 438582-80-0 438582-81-1 438582-82-2
438582-83-3 438582-84-4 438582-85-5
RL: PRP (Properties)
(Unclaimed; short peptides from the 'A-region' of protein kinases which selectively modulate protein kinase activity)

IT 56-41-7, L-Alanine, biological studies 79079-06-4, EGF receptor protein kinase 88201-45-0, Insulin receptor kinase 114051-78-4, LCK kinase 137010-36-7, NGF receptor tyrosine kinase 137632-06-5, CSK protein kinase 137632-07-6, ERK1 kinase 140208-17-9, LYN kinase 141349-89-5, SRC kinase 145539-86-2, HCK kinase 146279-92-7, Gene ret receptor protein tyrosine kinase 148640-14-6, Protein kinase B 153190-61-5, TYK2 protein kinase 161384-16-3, JAK kinase 162032-63-5, Discoidin domain receptor tyrosine kinase 165245-96-5, p38 MAP kinase 166433-56-3, ALK receptor tyrosine kinase 199015-85-5, Activin receptor-like kinase 372092-80-3, Protein kinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(peptides from A-region of protein kinases which selectively modulate protein kinase activity)

IT 438042-66-1 438042-66-1D, variant derivs. 438042-67-2 438042-67-2D, variant derivs. 438042-69-4 438042-69-4D, variant derivs.
438042-70-7 438042-70-7D, variant derivs. 438042-71-8 438042-71-8D, variant derivs. 438042-72-9 438042-72-9D, variant derivs.
438042-73-0 438042-73-0D, variant derivs. 438042-74-1 438042-74-1D, variant derivs. 438042-75-2 438042-75-2D, variant derivs.
438042-76-3 438042-76-3D, variant derivs. 438042-77-4 438042-77-4D, variant derivs. 438042-78-5 438042-78-5D, variant derivs.
438042-79-6 438042-79-6D, variant derivs. 438042-80-9 438042-80-9D, variant derivs. 438042-81-0 438042-81-0D, variant derivs.
438042-82-1 438042-82-1D, variant derivs. 438042-83-2 438042-83-2D, variant derivs. 438042-84-3 438042-84-3D, variant derivs.
438042-85-4 438042-85-4D, variant derivs. 438042-86-5 438042-86-5D, variant derivs. 438042-87-6 438042-87-6D, variant derivs.
438042-88-7 438042-88-7D, variant derivs. 438042-89-8 438042-89-8D, variant derivs. 438042-90-1 438042-90-1D, variant derivs.
438042-91-2 438042-91-2D, variant derivs. 438042-92-3 438042-92-3D, variant derivs. 438042-93-4 438042-93-4D, variant derivs.

438042-95-6 438042-95-6D, variant derivs. 438042-96-7 438042-96-7D, variant derivs. 438042-97-8 438042-97-8D, variant derivs. 438042-98-9 438042-98-9D, variant derivs. 438042-99-0 438042-99-0D, variant derivs. 438043-00-6 438043-00-6D, variant derivs. 438043-01-7 438043-01-7D, variant derivs. 438043-02-8 438043-02-8D, variant derivs. 438043-03-9 438043-03-9D, variant derivs. 438043-05-1 438043-05-1D, variant derivs. 438043-06-2 438043-06-2D, variant derivs. 438043-07-3 438043-07-3D, variant derivs. 438043-08-4 438043-08-4D, variant derivs. 438043-09-5 438043-09-5D, variant derivs. 438043-10-8 438043-10-8D, variant derivs. 438043-11-9 438043-11-9D, variant derivs. 438043-12-0 438043-12-0D, variant derivs. 438043-13-1 438043-13-1D, variant derivs. 438043-14-2 438043-14-2D, variant derivs. 438043-15-3 438043-15-3D, variant derivs. 438043-16-4 438043-16-4D, variant derivs. 438043-17-5 438043-17-5D, variant derivs. 438043-18-6 438043-18-6D, variant derivs. 438043-19-7 438043-19-7D, variant derivs. 438043-20-0 438043-20-0D, variant derivs. 438043-22-2 438043-22-2D, variant derivs. 438043-23-3 438043-23-3D, variant derivs. 438043-24-4 438043-24-4D, variant derivs. 438043-25-5 438043-25-5D, variant derivs. 438043-26-6 438043-26-6D, variant derivs. 438043-27-7 438043-27-7D, variant derivs. 438043-28-8 438043-28-8D, variant derivs. 438043-29-9 438043-29-9D, variant derivs. 438043-30-2 438043-30-2D, variant derivs. 438043-31-3 438043-31-3D, variant derivs. 438043-32-4 438043-32-4D, variant derivs. 438043-33-5 438043-33-5D, variant derivs. 438043-34-6 438043-34-6D, variant derivs. 438043-35-7 438043-35-7D, variant derivs. 438043-36-8 438043-36-8D, variant derivs. 438043-37-9 438043-37-9D, variant derivs. 438043-39-1 438043-39-1D, variant derivs. 438043-40-4 438043-40-4D, variant derivs. 438043-42-6 438043-43-7 438043-44-8 438043-45-9 438043-46-0 438043-47-1 438043-48-2 438043-49-3 438043-50-6 438043-51-7 438043-52-8 438043-53-9 438043-54-0 438043-55-1 438043-56-2 438043-57-3 438043-58-4 438043-59-5 438043-60-8 438043-61-9 438043-62-0 438043-63-1 438043-64-2 438043-65-3 438043-66-4 438043-67-5 438043-68-6 438043-69-7 438043-70-0 438043-71-1 438043-72-2 438043-73-3 438043-74-4 438043-75-5 438043-76-6 438043-77-7 438043-79-9 438043-81-3 438043-83-5 461638-41-5 461638-41-5D, variant derivs. 461638-42-6 461638-42-6D, variant derivs. 461638-43-7 461638-43-7D, variant derivs. 461638-44-8 461638-44-8D, variant derivs. 461638-45-9 461638-45-9D, variant derivs. 461638-46-0 461638-46-0D, variant derivs. 461638-47-1 461638-47-1D, variant derivs. 461638-48-2 461638-48-2D, variant derivs.
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptides from A-region of protein kinases which selectively modulate protein kinase activity)

IT 438582-71-9
RL: PRP (Properties)
(unclaimed sequence; short peptides from the 'A-region' of protein kinases which selectively modulate protein kinase activity)

IT 50-99-7, D-Glucose, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(uptake; peptides from A-region of protein kinases which selectively modulate protein kinase activity)

L45 ANSWER 6 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN
AN **2002:675784** HCAPLUS
DN 137:210957
ED Entered STN: 08 Sep 2002
TI sequences of protein 14273 from human and mouse, and methods for the treatment of metabolic disorders, including obesity and diabetes
IN Gimeno, Ruth; Tsai, Fong-Ying
PA Millennium Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 95 pp.
CODEN: PIXXD2

DT Patent
LA English
IC ICM A61K
CC 1-10 (Pharmacology)
Section cross-reference(s): 3, 6, 13
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002067868	A2	20020906	WO 2002-US6131	20020226
	WO 2002067868	A3	20030306		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	US 2002177151	A1	20021128	US 2002-86181	20020226
PRAI	US 2001-271655P	P	20010226		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002067868	ICM	A61K
WO 2002067868	ECLA	C07K014/705; C07K014/72B; C12Q001/68M6
US 2002177151	NCL	435/006.000; 435/091.200
	ECLA	C07K014/705; C07K014/72B; C12Q001/68M6

AB The present invention provides protein and cDNA sequences of human and mouse protein 14273 that are expressed at high levels in adipose tissues (white and brown adipose tissues) and pancreatic tissues. The 14273 gene expression has been further found to be upregulated during exposure to cold, and down-regulated in genetic model of obesity. The present invention relates to methods and compns. for the diagnosis and treatment of metabolic disorders, including, but not limited to, obesity, diabetes, overweight, anorexia, or cachexia. The invention further provides methods for identifying a compound capable of treating a metabolic disorder. The invention also provides methods for identifying a compound capable of modulating a metabolic activity. Yet further, the invention provides a method for modulating a metabolic activity. In addition, the invention provides a method for treating a subject having a metabolic disorder characterized by aberrant 14273 polypeptide activity or aberrant 14273 nucleic acid expression. In another aspect, the invention provides methods for modulating lipogenesis in a subject and methods for modulating lipolysis in a subject. In yet another aspect, the invention provides methods for regulating endogenous glucose levels.

ST sequence protein human mouse metabolic disorder obesity diabetes therapy
IT Proteins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(14273; sequences of protein 14273 from human and mouse, and methods for treatment of metabolic disorders, including obesity and diabetes)
IT Adipose tissue
(adipocyte, hyperplastic or hypertrophic growth, treatment of; sequences of protein 14273 from human and mouse, and methods for treatment of metabolic disorders, including obesity and diabetes)
IT Gel electrophoresis
(agarose, for detecting 14273; sequences of protein 14273 from human and mouse, and methods for treatment of metabolic disorders, including obesity and diabetes)
IT Antisense DNA
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-14273; sequences of protein 14273 from human and mouse, and

methods for treatment of metabolic disorders, including obesity and diabetes)

IT Adipose tissue
(brown, high level of 14273 gene expression in; sequences of protein 14273 from human and mouse, and methods for treatment of metabolic disorders, including obesity and diabetes)

IT Metabolism, animal
(disorder, treatment of; sequences of protein 14273 from human and mouse, and methods for treatment of metabolic disorders, including obesity and diabetes)

IT mRNA
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(encoding protein 14273, tissue distribution; sequences of protein 14273 from human and mouse, and methods for treatment of metabolic disorders, including obesity and diabetes)

IT Northern blot hybridization
Nucleic acid amplification (method)
Southern blot hybridization
(for detecting 14273; sequences of protein 14273 from human and mouse, and methods for treatment of metabolic disorders, including obesity and diabetes)

IT Nucleic acid hybridization
(for detecting the presence of protein 14273 in a sample; sequences of protein 14273 from human and mouse, and methods for treatment of metabolic disorders, including obesity and diabetes)

IT Genetic vectors
(for expressing protein 14273; sequences of protein 14273 from human and mouse, and methods for treatment of metabolic disorders, including obesity and diabetes)

IT Gene therapy
(for modulating the levels or activities of protein 14273; sequences of protein 14273 from human and mouse, and methods for treatment of metabolic disorders, including obesity and diabetes)

IT Nucleic acid hybridization
(in situ, for detecting 14273; sequences of protein 14273 from human and mouse, and methods for treatment of metabolic disorders, including obesity and diabetes)

IT Antibodies and Immunoglobulins
RL: ARG (Analytical reagent use); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(labeled, to protein 14273; sequences of protein 14273 from human and mouse, and methods for treatment of metabolic disorders, including obesity and diabetes)

IT Primers (nucleic acid)
Probes (nucleic acid)
RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(labeled; sequences of protein 14273 from human and mouse, and methods for treatment of metabolic disorders, including obesity and diabetes)

IT **Lipids, biological studies**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(lipolysis, modulation of; sequences of protein 14273 from human and mouse, and methods for treatment of metabolic disorders, including obesity and diabetes)

IT Second messenger system
(modulation of; sequences of protein 14273 from human and mouse, and methods for treatment of metabolic disorders, including obesity and diabetes)

IT Diagnosis
(mol.; sequences of protein 14273 from human and mouse, and methods for treatment of metabolic disorders, including obesity and diabetes)

IT Mutagenesis
(on 14273 gene; sequences of protein 14273 from human and mouse, and methods for treatment of metabolic disorders, including obesity and diabetes)

IT **Lipids, biological studies**
RL: BSU (Biological study, unclassified); BIOL (Biological study)

(production, modulation of; sequences of protein 14273 from human and mouse, and methods for treatment of metabolic disorders, including obesity and diabetes)

IT Antidiabetic agents
Antiobesity agents
Drug screening
Human
Molecular cloning
Protein sequences
cDNA sequences
(sequences of protein 14273 from human and mouse, and methods for treatment of metabolic disorders, including obesity and diabetes)

IT Antibodies and Immunoglobulins
RL: ARG (Analytical reagent use); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(to protein 14273; sequences of protein 14273 from human and mouse, and methods for treatment of metabolic disorders, including obesity and diabetes)

IT Mus
(transgenic; sequences of protein 14273 from human and mouse, and methods for treatment of metabolic disorders, including obesity and diabetes)

IT Diabetes mellitus
Obesity
(treatment of; sequences of protein 14273 from human and mouse, and methods for treatment of metabolic disorders, including obesity and diabetes)

IT Adipose tissue
(white, high level of 14273 gene expression in; sequences of protein 14273 from human and mouse, and methods for treatment of metabolic disorders, including obesity and diabetes)

IT 456538-24-2P, Protein (human clone 14273) 456538-26-4P, Protein (mouse clone 14273)
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; sequences of protein 14273 from human and mouse, and methods for treatment of metabolic disorders, including obesity and diabetes)

IT 9012-36-6, Agarose
RL: DEV (Device component use); USES (Uses)
(gel electrophoresis, for detecting 14273; sequences of protein 14273 from human and mouse, and methods for treatment of metabolic disorders, including obesity and diabetes)

IT 456538-23-1 456538-25-3
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nucleotide sequence; sequences of protein 14273 from human and mouse, and methods for treatment of metabolic disorders, including obesity and diabetes)

IT 456540-70-8, 3: PN: WO02067868 SEQID: 3 unclaimed DNA 456540-71-9, 6: PN: WO02067868 SEQID: 6 unclaimed DNA 456540-72-0 456540-73-1 456540-74-2 456540-75-3 456540-76-4 456540-77-5 456540-78-6 456540-79-7 456540-80-0 456540-81-1
RL: PRP (Properties)
(unclaimed nucleotide sequence; sequences of protein 14273 from human and mouse, and methods for treatment of metabolic disorders, including obesity and diabetes)

L45 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN
AN **2002:466175** HCAPLUS
DN 137:43447
ED Entered STN: 21 Jun 2002
TI Short peptides from the "A-region" of protein kinases which selectively modulate kinase activity and kinase-associated signal transduction and their therapeutic use

IN Ben-Sasson, Shmuel
PA Children's Medical Center Corporation, USA; Yissum Research and Development
SO PCT Int. Appl., 143 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C12N009-12
ICS A61K038-45; C12Q001-48
CC 7-3 (Enzymes)
Section cross-reference(s): 1
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002048336	A2	20020620	WO 2001-US47443	20011211
	WO 2002048336	A3	20030313		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2002115173	A1	20020822	US 2000-734520	20001211
	AU 2002028912	A5	20020624	AU 2002-28912	20011211
PRAI	US 2000-734520	A	20001211		
	WO 2001-US47443	W	20011211		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002048336	ICM	C12N009-12
	ICS	A61K038-45; C12Q001-48
WO 2002048336	ECLA	C12N009/12B1
US 2002115173	NCL	435/194.000; 435/070.210; 435/007.920
	ECLA	C12N009/12B1

OS MARPAT 137:43447
AB The present invention concerns compds. comprising, within short sequences from a specific region of the kinase, that can modulate kinase-associated signal transduction. The present invention allows a method for identifying compds. that are candidates for modulating kinase-associated signal transduction. The present invention also enables obtaining compds. that can modulate the kinase-associated signal transduction. The present invention also concerns a method for the modulation of kinase-associated signal transduction comprising the administration of the compds. This method may be used for the treatment of a plurality of diseases that are caused by or are result of non-normal kinase activity.
ST protein kinase A region peptide signal transduction therapeutic
IT Adipose tissue
(adipocyte, lipogenesis by; short peptides from A-region of protein kinases which selectively modulate kinase activity and kinase-associated signal transduction and their therapeutic use)
IT Antiarteriosclerotics
(antiatherosclerotics; short peptides from A-region of protein kinases which selectively modulate kinase activity and kinase-associated signal transduction and their therapeutic use)
IT Nervous system, disease
(central, treatment of; short peptides from A-region of protein kinases which selectively modulate kinase activity and kinase-associated signal transduction and their therapeutic use)
IT Nervous system, disease
(degeneration, treatment of; short peptides from A-region of protein kinases which selectively modulate kinase activity and kinase-associated signal transduction and their therapeutic use)
IT Bone, disease

(healing, in signal transduction test assay; short peptides from A-region of protein kinases which selectively modulate kinase activity and kinase-associated signal transduction and their therapeutic use)

IT Appetite
Biological transport
Body weight
Granulation tissue
Infection
Inflammation
Neoplasm
(in signal transduction test assay; short peptides from A-region of protein kinases which selectively modulate kinase activity and kinase-associated signal transduction and their therapeutic use)

IT Cytokines
Hormones, animal, biological studies
RL: ANT (Analyte); BSU (Biological study, unclassified); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(in signal transduction test assay; short peptides from A-region of protein kinases which selectively modulate kinase activity and kinase-associated signal transduction and their therapeutic use)

IT **Lipids, biological studies**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(lipogenesis by adipocytes; short peptides from A-region of protein kinases which selectively modulate kinase activity and kinase-associated signal transduction and their therapeutic use)

IT Neoplasm
(metastasis, in signal transduction test assay; short peptides from A-region of protein kinases which selectively modulate kinase activity and kinase-associated signal transduction and their therapeutic use)

IT Axon
(outgrowth, in signal transduction test assay; short peptides from A-region of protein kinases which selectively modulate kinase activity and kinase-associated signal transduction and their therapeutic use)

IT Phosphorylation, biological
(protein; short peptides from A-region of protein kinases which selectively modulate kinase activity and kinase-associated signal transduction and their therapeutic use)

IT Animal tissue
(remodeling, in signal transduction test assay; short peptides from A-region of protein kinases which selectively modulate kinase activity and kinase-associated signal transduction and their therapeutic use)

IT Artery, disease
(restenosis, treatment of; short peptides from A-region of protein kinases which selectively modulate kinase activity and kinase-associated signal transduction and their therapeutic use)

IT Anti-inflammatory agents
Antidiabetic agents
Antiobesity agents
Antitumor agents
Cell differentiation
Cell morphology
Cell proliferation
Drug screening
Immunomodulators
Peptidomimetics
Protein sequences
Secretion (process)
Signal transduction, biological
(short peptides from A-region of protein kinases which selectively modulate kinase activity and kinase-associated signal transduction and their therapeutic use)

IT Peptides, biological studies
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(short peptides from A-region of protein kinases which selectively modulate kinase activity and kinase-associated signal transduction and

their therapeutic use)

IT Osteoporosis
(therapeutic agents; short peptides from A-region of protein kinases which selectively modulate kinase activity and kinase-associated signal transduction and their therapeutic use)

IT Alopecia
Autoimmune disease
Cardiovascular system, disease
Skin, disease
(treatment of; short peptides from A-region of protein kinases which selectively modulate kinase activity and kinase-associated signal transduction and their therapeutic use)

IT Biological transport
(uptake, of glucose; short peptides from A-region of protein kinases which selectively modulate kinase activity and kinase-associated signal transduction and their therapeutic use)

IT Amino acids, biological studies
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(D-; short peptides from A-region of protein kinases which selectively modulate kinase activity and kinase-associated signal transduction and their therapeutic use)

IT 142008-29-5, Protein kinase A
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Cα subunit; short peptides from A-region of protein kinases which selectively modulate kinase activity and kinase-associated signal transduction and their therapeutic use)

IT 88201-45-0, Insulin receptor kinase 114051-78-4, LCK kinase
137010-36-7, NGF receptor tyrosine kinase 137632-06-5, CSK protein kinase 140208-17-9, LYN kinase 141349-89-5, SRC kinase 145539-86-2, HCK kinase 146279-92-7, Gene ret receptor tyrosine kinase 153190-61-5, Tyk2 kinase 161384-16-3, Jak kinase 162032-63-5, Discoidin domain receptor tyrosine kinase 199015-85-5, Activin receptor-like kinase 372092-80-3, Protein kinase 386705-49-3, VEGF receptor tyrosine kinase
438042-66-1 438042-67-2 438042-68-3 438042-69-4 438042-70-7
438042-71-8 438042-72-9 438042-73-0 438042-74-1 438042-75-2
438042-76-3 438042-77-4 438042-78-5 438042-79-6 438042-80-9
438042-81-0 438042-82-1 438042-83-2 438042-84-3 438042-85-4
438042-86-5 438042-87-6 438042-88-7 438042-89-8 438042-90-1
438042-91-2 438042-92-3 438042-93-4 438042-94-5 438042-95-6
438042-96-7 438042-97-8 438042-98-9 438042-99-0 438043-00-6
438043-01-7 438043-02-8 438043-03-9 438043-04-0 438043-05-1
438043-06-2 438043-07-3 438043-08-4 438043-09-5 438043-10-8
438043-11-9 438043-12-0 438043-13-1 438043-14-2 438043-15-3
438043-16-4 438043-17-5 438043-18-6 438043-19-7 438043-20-0
438043-21-1 438043-22-2 438043-23-3 438043-24-4 438043-25-5
438043-26-6 438043-27-7 438043-28-8 438043-29-9 438043-30-2
438043-31-3 438043-32-4 438043-33-5 438043-34-6 438043-35-7
438043-36-8 438043-37-9 438043-38-0 438043-39-1 438043-40-4
438043-41-5 438043-42-6 438043-43-7 438043-44-8 438043-45-9
438043-46-0 438043-47-1 438043-48-2 438043-49-3 438043-50-6
438043-51-7 438043-52-8 438043-53-9 438043-54-0 438043-55-1
438043-56-2 438043-57-3 438043-58-4 438043-59-5 438043-60-8
438043-61-9 438043-62-0 438043-63-1 438043-64-2 438043-65-3
438043-66-4 438043-67-5 438043-68-6 438043-69-7 438043-70-0
438043-71-1 438043-72-2 438043-73-3 438043-74-4 438043-75-5
438043-76-6 438043-77-7 438043-79-9 438043-81-3 438043-83-5
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(short peptides from A-region of protein kinases which selectively modulate kinase activity and kinase-associated signal transduction and their therapeutic use)

IT 56-41-7, L-Alanine, biological studies
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(short peptides from A-region of protein kinases which selectively modulate kinase activity and kinase-associated signal transduction and their therapeutic use)

IT 438582-71-9 438582-72-0 438582-73-1 438582-74-2 438582-75-3
438582-76-4 438582-77-5 438582-79-7 438582-80-0 438582-81-1
438582-82-2 438582-83-3 438582-84-4 438582-85-5
RL: PRP (Properties)
(unclaimed sequence; short peptides from the "A-region" of protein kinases which selectively modulate kinase activity and kinase-associated signal transduction and their therapeutic use)

IT 50-99-7, Glucose, biological studies
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(uptake and blood level; short peptides from A-region of protein kinases which selectively modulate kinase activity and kinase-associated signal transduction and their therapeutic use)

L45 ANSWER 8 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN
AN **2002:172081** HCAPLUS
DN 136:227973
ED Entered STN: 08 Mar 2002
TI Protein and cDNA sequences of a novel human G protein-coupled receptor sequence homolog and diagnostic and therapeutic uses thereof for metabolic disorders
IN Glucksmann, Maria Alexdandra
PA Millennium Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 114 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C12N015-00
CC 3-3 (Biochemical Genetics)
Section cross-reference(s): 1, 6, 13

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002018579	A2	20020307	WO 2001-US26882	20010829
	WO 2002018579	A3	20030417		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2001086877	A5	20020313	AU 2001-86877	20010829
	US 2002137063	A1	20020926	US 2001-942374	20010829
	US 2004086921	A1	20040506	US 2003-665956	20030918
PRAI	US 2000-228409P	P	20000829		
	US 2001-942374	B1	20010829		
	WO 2001-US26882	W	20010829		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002018579	ICM	C12N015-00
WO 2002018579	ECLA	C07K014/705
US 2002137063	NCL	435/006.000; 435/007.100; 435/069.100; 435/320.100; 435/325.000; 530/350.000; 530/388.100; 536/023.500
	ECLA	C07K014/705
US 2004086921	NCL	435/006.000; 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
	ECLA	C07K014/705

AB The invention provides protein and cDNA sequences of a novel human

protein, designated 57242, which has sequence homol. with G protein-coupled receptor family members. The invention also provides antisense nucleic acid mols., recombinant expression vectors containing 57242 nucleic acid mols., host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 57242 gene has been introduced or disrupted. The invention still further provides isolated 57242 proteins, fusion proteins, antigenic peptides and anti-57242 antibodies. Methods of use of the provided 57242 compns. for screening, diagnostic and therapeutic methods in connection with metabolic disorders are also disclosed. The present invention relates to methods and compns. for the diagnosis and treatment of metabolic disorders, including, but not limited to, obesity, diabetes, hyperlipidemia, overweight anorexia, or cachexia.

ST G protein coupled receptor homolog cDNA sequence human

IT Disease, animal
(adipose tissue, hyperplastic or hypertrophic, treatment of; protein and cDNA sequences of novel human G protein-coupled receptor sequence homolog and diagnostic and therapeutic uses thereof for metabolic disorders)

IT Adipose tissue
(disease, hyperplastic or hypertrophic, treatment of; protein and cDNA sequences of novel human G protein-coupled receptor sequence homolog and diagnostic and therapeutic uses thereof for metabolic disorders)

IT Metabolism, animal
(disorder, treatment of; protein and cDNA sequences of novel human G protein-coupled receptor sequence homolog and diagnostic and therapeutic uses thereof for metabolic disorders)

IT Bone formation
(disorders associated with, treatment of; protein and cDNA sequences of novel human G protein-coupled receptor sequence homolog and diagnostic and therapeutic uses thereof for metabolic disorders)

IT DNA
RL: ANT (Analyte); ANST (Analytical study)
(encoding 57242, detection of; protein and cDNA sequences of novel human G protein-coupled receptor sequence homolog and diagnostic and therapeutic uses thereof for metabolic disorders)

IT cDNA
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(encoding G protein-coupled receptor sequence homolog 57242; protein and cDNA sequences of novel human G protein-coupled receptor sequence homolog and diagnostic and therapeutic uses thereof for metabolic disorders)

IT Test kits
(for detecting G protein-coupled receptor sequence homolog 57242; protein and cDNA sequences of novel human G protein-coupled receptor sequence homolog and diagnostic and therapeutic uses thereof for metabolic disorders)

IT Gel electrophoresis
Immunoassay
Northern blot hybridization
Nucleic acid hybridization
Southern blot hybridization
(for detecting the presence of G protein-coupled receptor sequence homolog in a sample; protein and cDNA sequences of novel human G protein-coupled receptor sequence homolog and diagnostic and therapeutic uses thereof for metabolic disorders)

IT Genetic vectors
(for expressing G protein-coupled receptor sequence homolog 57242; protein and cDNA sequences of novel human G protein-coupled receptor sequence homolog and diagnostic and therapeutic uses thereof for metabolic disorders)

IT Gene therapy
(for modulating the levels or activities of 57242; protein and cDNA sequences of novel human G protein-coupled receptor sequence homolog and diagnostic and therapeutic uses thereof for metabolic disorders)

IT Diagnosis

(genetic; protein and cDNA sequences of novel human G protein-coupled receptor sequence homolog and diagnostic and therapeutic uses thereof for metabolic disorders)

IT **Lipids, biological studies**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(hyperlipidemia, treatment of; protein and cDNA sequences of novel human G protein-coupled receptor sequence homolog and diagnostic and therapeutic uses thereof for metabolic disorders)

IT Nucleic acid hybridization
(in situ, for detecting the presence of G protein-coupled receptor sequence homolog in a sample; protein and cDNA sequences of novel human G protein-coupled receptor sequence homolog and diagnostic and therapeutic uses thereof for metabolic disorders)

IT **Lipids, biological studies**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(lipolysis, disorders associated with, treatment of; protein and cDNA sequences of novel human G protein-coupled receptor sequence homolog and diagnostic and therapeutic uses thereof for metabolic disorders)

IT Animal cell
(mammalian, as host; protein and cDNA sequences of novel human G protein-coupled receptor sequence homolog and diagnostic and therapeutic uses thereof for metabolic disorders)

IT **Lipids, biological studies**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(metabolic disorders, lipogenesis, treatment of; protein and cDNA sequences of novel human G protein-coupled receptor sequence homolog and diagnostic and therapeutic uses thereof for metabolic disorders)

IT Antisense DNA
Ribozymes
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(modulator for 57242 expression or activity; protein and cDNA sequences of novel human G protein-coupled receptor sequence homolog and diagnostic and therapeutic uses thereof for metabolic disorders)

IT Diagnosis
(mol.; protein and cDNA sequences of novel human G protein-coupled receptor sequence homolog and diagnostic and therapeutic uses thereof for metabolic disorders)

IT Antidiabetic agents
Antiobesity agents
Drug screening
Human
Molecular cloning
Protein sequences
cDNA sequences
(protein and cDNA sequences of novel human G protein-coupled receptor sequence homolog and diagnostic and therapeutic uses thereof for metabolic disorders)

IT Primers (nucleic acid)
Probes (nucleic acid)
RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(protein and cDNA sequences of novel human G protein-coupled receptor sequence homolog and diagnostic and therapeutic uses thereof for metabolic disorders)

IT G protein-coupled receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(sequence homolog; protein and cDNA sequences of novel human G protein-coupled receptor sequence homolog and diagnostic and therapeutic uses thereof for metabolic disorders)

IT Antibodies and Immunoglobulins
RL: ARG (Analytical reagent use); BSU (Biological study, unclassified); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(to G protein-coupled receptor sequence homolog; protein and cDNA sequences of novel human G protein-coupled receptor sequence homolog and diagnostic and therapeutic uses thereof for metabolic disorders)

IT Anorexia
Bone, disease
Cachexia
(treatment of; protein and cDNA sequences of novel human G protein-coupled receptor sequence homolog and diagnostic and therapeutic uses thereof for metabolic disorders)
IT 403067-53-8P
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; protein and cDNA sequences of novel human G protein-coupled receptor sequence homolog and diagnostic and therapeutic uses thereof for metabolic disorders)
IT 403067-52-7 403067-54-9
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nucleotide sequence; protein and cDNA sequences of novel human G protein-coupled receptor sequence homolog and diagnostic and therapeutic uses thereof for metabolic disorders)
IT 403070-95-1, 4: PN: WO0218579 SEQID: 4 unclaimed DNA 403070-96-2, 5: PN: WO0218579 SEQID: 5 unclaimed DNA 403070-97-3, 6: PN: WO0218579 SEQID: 6 unclaimed DNA 403070-98-4, 7: PN: WO0218579 SEQID: 7 unclaimed DNA 403070-99-5, 8: PN: WO0218579 SEQID: 8 unclaimed DNA 403071-00-1, 9: PN: WO0218579 SEQID: 9 unclaimed DNA
RL: PRP (Properties)
(unclaimed nucleotide sequence; protein and cDNA sequences of a novel human G protein-coupled receptor sequence homolog and diagnostic and therapeutic uses thereof for metabolic disorders)

L45 ANSWER 9 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN
AN **2000:573930** HCAPLUS
DN 133:159935
ED Entered STN: 18 Aug 2000
TI Inhibiting formation of atherosclerotic lesions by reducing adipocyte fatty acid binding protein (AFABP)
IN Haber, Edgar; Lee, Mu-en; Perrella, Mark A.; Hotamisligil, Gokhan S.
PA President and Fellows of Harvard College, USA; Haber, Carol
SO PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C12N015-11
ICS A61K031-7088; A61K039-395; G01N033-68
CC 1-8 (Pharmacology)
Section cross-reference(s): 3, 14
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000047734	A1	20000817	WO 2000-US3560	20000211
	W: AU, CA, JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2361335	AA	20000817	CA 2000-2361335	20000211
	EP 1151092	A1	20011107	EP 2000-908604	20000211
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002536459	T2	20021029	JP 2000-598632	20000211
PRAI	US 1999-119880P	A2	19990212		
	WO 2000-US3560	W	20000211		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2000047734	ICM	C12N015-11
	ICS	A61K031-7088; A61K039-395; G01N033-68
WO 2000047734	ECLA	C12N015/11B

AB The invention features a method of inhibiting formation of atherosclerotic

lesions by administering to a mammal, e.g., a human patient who has been identified as suffering from or at risk of developing atherosclerosis, a compound that reduces expression or activity of adipocyte fatty acid binding protein (AFABP or aP2). Inhibiting AFABP expression or activity reduced the development of atherosclerotic lesions despite a high level of serum cholesterol. Mice with a null mutation in the genes for apoE or both apoE and AFABP were used for the study.

ST atherosclerosis inhibition adipocyte fatty acid binding protein; aP2 protein antiatherosclerotic

IT Hypercholesterolemia
(AFABP-deficient mice resistance to; inhibiting formation of atherosclerotic lesions by reducing adipocyte fatty acid binding protein (AFABP))

IT Apolipoproteins
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(E, gene for, null mutation in; inhibiting formation of atherosclerotic lesions by reducing adipocyte fatty acid binding protein (AFABP))

IT Phosphoproteins
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
(aP2 (adipocyte protein 2); inhibiting formation of atherosclerotic lesions by reducing adipocyte fatty acid binding protein (AFABP))

IT Adipose tissue
(adipocyte, inhibition of AFABP expression in; inhibiting formation of atherosclerotic lesions by reducing adipocyte fatty acid binding protein (AFABP))

IT Antiarteriosclerotics
(antiatherosclerotics; inhibiting formation of atherosclerotic lesions by reducing adipocyte fatty acid binding protein (AFABP))

IT Antisense DNA
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(as inhibitor; inhibiting formation of atherosclerotic lesions by reducing adipocyte fatty acid binding protein (AFABP))

IT Antisense oligonucleotides
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as inhibitor; inhibiting formation of atherosclerotic lesions by reducing adipocyte fatty acid binding protein (AFABP))

IT Genetic element
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(cis regulatory element, of AFABP, inhibition of; inhibiting formation of atherosclerotic lesions by reducing adipocyte fatty acid binding protein (AFABP))

IT **Fatty acids, biological studies**
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(complexes, with AFABP, in drug screening; inhibiting formation of atherosclerotic lesions by reducing adipocyte fatty acid binding protein (AFABP))

IT Cell
(expressing AFABP, in drug screening; inhibiting formation of atherosclerotic lesions by reducing adipocyte fatty acid binding protein (AFABP))

IT Artery
(foam cell, inhibition of macrophage differentiation into; inhibiting formation of atherosclerotic lesions by reducing adipocyte fatty acid binding protein (AFABP))

IT mRNA
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(for AFABP, antisense nucleic acid to, as inhibitor; inhibiting

formation of atherosclerotic lesions by reducing adipocyte fatty acid binding protein (AFABP))

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
(for apoE and AFABP, null mutation in; inhibiting formation of atherosclerotic lesions by reducing adipocyte fatty acid binding protein (AFABP))

IT **Fatty acids, biological studies**
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(in drug screening; inhibiting formation of atherosclerotic lesions by reducing adipocyte fatty acid binding protein (AFABP))

IT Artery
Drug screening
Mammal (Mammalia)
(inhibiting formation of atherosclerotic lesions by reducing adipocyte fatty acid binding protein (AFABP))

IT Macrophage
(inhibition of AFABP expression in; inhibiting formation of atherosclerotic lesions by reducing adipocyte fatty acid binding protein (AFABP))

IT Promoter (genetic element)
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(macrophage-specific, antisense DNA linked to; inhibiting formation of atherosclerotic lesions by reducing adipocyte fatty acid binding protein (AFABP))

IT Transcription, genetic
(of AFABP, inhibition of; inhibiting formation of atherosclerotic lesions by reducing adipocyte fatty acid binding protein (AFABP))

IT Cell differentiation
(of macrophage into foam cell, inhibition of; inhibiting formation of atherosclerotic lesions by reducing adipocyte fatty acid binding protein (AFABP))

IT 57-88-5, Cholesterol, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(inhibiting formation of atherosclerotic lesions by reducing adipocyte fatty acid binding protein (AFABP))

IT 139817-95-1, 7: PN: WO0047734 SEQID: 1 unclaimed DNA 140602-12-6
288106-38-7, 1: PN: WO0047734 SEQID: 2 unclaimed DNA
RL: PRP (Properties)
(unclaimed nucleotide sequence; inhibiting formation of atherosclerotic lesions by reducing adipocyte fatty acid binding protein (AFABP))

IT 123505-46-4, Phosphoprotein ALBP (human clone λH-ALBP precursor protein moiety reduced) 288106-39-8
RL: PRP (Properties)
(unclaimed protein sequence; inhibiting formation of atherosclerotic lesions by reducing adipocyte fatty acid binding protein (AFABP))

IT 220264-61-9 288067-91-4
RL: PRP (Properties)
(unclaimed sequence; inhibiting formation of atherosclerotic lesions by reducing adipocyte fatty acid binding protein (AFABP))

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Dana Farber Cancer Inst Inc; WO 9206104 A 1992 HCAPLUS
(2) Horvai, A; PROC NATL ACAD SCI U S A 1995, V92(12), P5391 HCAPLUS
(3) Hotamisligil, G; SCIENCE 1996, V274(5291), P1377 HCAPLUS
(4) Incyte Pharma Inc; WO 9845440 A 1998 HCAPLUS
(5) Lyle, R; BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 1996, V228(3), P709 HCAPLUS
(6) Pelton, P; BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 1999, V261(2), P456 HCAPLUS
(7) Richieri, G; JOURNAL OF BIOLOGICAL CHEMISTRY 1994, V269(39), P23918 HCAPLUS
(8) Squibb Bristol Myers Co; WO 0015230 A 2000 HCAPLUS

(9) Wolfrum, C; BIOCHIMICA ET BIOPHYSICA ACTA 1999, V1437(2), P194 HCAPLUS

L45 ANSWER 10 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN
AN **2000:548711** HCAPLUS
DN 133:129884
ED Entered STN: 10 Aug 2000
TI Modulation of the sulfonylurea receptor and calcium in adipocytes for treatment of obesity/diabetes, and screening method
IN Wilkison, William O.; Zemel, Michael B.; Moustaid-Mousse, Naima
PA Zen Bio, Inc., USA; The University of Tennessee Research Corporation
SO U.S., 17 pp.
CODEN: USXXAM
DT Patent
LA English
IC ICM G01N033-566
ICS G01N033-567
INCL 435007200
CC 1-10 (Pharmacology)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6100047	A	20000808	US 1999-287907	19990407
	US 6242200	B1	20010605	US 2000-592420	20000612
	US 6492130	B1	20021210	US 2000-592019	20000612
	US 6569633	B1	20030527	US 2000-592421	20000612
PRAI	US 1998-81189P	P	19980408		
	US 1999-287907	A3	19990407		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 6100047	ICM	G01N033-566
	ICS	G01N033-567
	INCL	435007200
US 6100047	NCL	435/007.200; 435/007.100; 435/007.210
	ECLA	G01N033/50D2; G01N033/92
US 6242200	NCL	435/007.210; 435/007.100; 435/007.200
	ECLA	G01N033/50D2; G01N033/92
US 6492130	NCL	435/014.000; 435/007.210; 435/026.000
	ECLA	G01N033/50D2; G01N033/92
US 6569633	NCL	435/007.210; 435/007.100; 435/007.200
	ECLA	G01N033/50D2; G01N033/92

AB Methods are provided for identifying compds. and compns. useful in the regulation of weight, the treatment of obesity, diabetes and other insulin resistance-related disorders hypertension, cardiovascular disease, etc. The methods comprise the use of adipocytes and preadipocytes in assays and screens for compds. or compns. of interest. The invention recognizes the presence of the sulfonylurea receptor in adipocytes and its utility in identifying compds. and in treating obesity and other insulin resistance-related disorders. The methods of the invention also provide for identifying novel calcium channels or other calcium regulatory channels that are selectively expressed in human adipocytes as compared to human preadipocytes and for screening adipocytes for compds. that selectively antagonize calcium. These compds. may be used in the treatment of obesity and diabetes and other insulin resistance-related disorders. Once identified, the compds. of the invention can be used in pharmaceutical compns. for the treatment of insulin resistance-related disorders and to regulate lipogenesis and lipolysis.

ST sulfonyl receptor modulation adipocyte obesity diabetes drug screening; calcium channel adipocyte obesity diabetes drug screening; insulin resistance disorder drug screening; hypertension cardiovascular disease drug screening; lipogenesis lipolysis drug screening

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(SUR1; sulfonylurea receptor and calcium modulation in adipocytes for treatment of obesity/diabetes, and screening method)

IT Adipose tissue
(adipocyte; sulfonylurea receptor and calcium modulation in adipocytes for treatment of obesity/diabetes, and screening method)
IT Ion channel blockers
(calcium; sulfonylurea receptor and calcium modulation in adipocytes for treatment of obesity/diabetes, and screening method)
IT Biological transport
(influx; sulfonylurea receptor and calcium modulation in adipocytes for treatment of obesity/diabetes, and screening method)
IT **Lipids, biological studies**
RL: BPR (Biological process); BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative); PROC (Process)
(lipogenesis; sulfonylurea receptor and calcium modulation in adipocytes for treatment of obesity/diabetes, and screening method)
IT **Lipids, biological studies**
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(lipolysis; sulfonylurea receptor and calcium modulation in adipocytes for treatment of obesity/diabetes, and screening method)
IT Antidiabetic agents
Antiobesity agents
Drug screening
(sulfonylurea receptor and calcium modulation in adipocytes for treatment of obesity/diabetes, and screening method)
IT Calcium channel
Glycerides, biological studies
Potassium channel
Sulfonylurea receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(sulfonylurea receptor and calcium modulation in adipocytes for treatment of obesity/diabetes, and screening method)
IT 9004-10-8, Insulin, biological studies 9045-77-6, Fatty acid synthase 9075-65-4, Glycerol-3-phosphate dehydrogenase
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(sulfonylurea receptor and calcium modulation in adipocytes for treatment of obesity/diabetes, and screening method)
IT 364-98-7, Diazoxide 11024-24-1, Digitonin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(sulfonylurea receptor and calcium modulation in adipocytes for treatment of obesity/diabetes, and screening method)
IT 10238-21-8, Glibenclamide 21829-25-4, Nifedipine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sulfonylurea receptor and calcium modulation in adipocytes for treatment of obesity/diabetes, and screening method)
IT 50-99-7, D-Glucose, biological studies 56-81-5, 1,2,3-Propanetriol, biological studies 60-92-4 7440-70-2, Calcium, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(sulfonylurea receptor and calcium modulation in adipocytes for treatment of obesity/diabetes, and screening method)
RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Abel; American Journal of Hypertension 1993, V6(6 Pt 1), P500 MEDLINE
(2) Aguilar-Bryan; Science 1995, V268, P423 HCAPLUS
(3) Alemzadeh; Endocrinology 1993, V133(2), P705 HCAPLUS
(4) Alemzadeh; J Clin Endocr Met 1998, V83(6), P1911 HCAPLUS
(5) Alemzadeh; Metabolism 1996, V45(4), P334
(6) Ambrozy; American Journal of Hypertension 1991, V4(7 Pt 1), P592 MEDLINE
(7) Bokvist; Proc R Soc Lond 1991, V243(1307), P139 HCAPLUS

(8) Byyny; American Journal of Hypertension 1992, V5(7), P459 MEDLINE
(9) Draznin; Diabetes 1987, V36, P174 HCAPLUS
(10) Draznin; The Journal of Biological Chemistry 1987, V262(30), P14385 HCAPLUS
(11) Draznin; The Journal of Clinical Investigation 1988, V82(6), P1848 HCAPLUS
(12) Gilon; The Journal of Biological Chemistry 1993, V268(30), P22265 HCAPLUS
(13) Hani; Diabetes 1997, V46(4), P688 HCAPLUS
(14) Inagaki; Science 1995, V270, P1166 HCAPLUS
(15) Jacobs; J Biol Chem 1985, V260(5), P2593 HCAPLUS
(16) Jones; Am J Physiol 1996, V270, PE192 HCAPLUS
(17) Jones; Endocrinology 1997, V138(4), P1512 HCAPLUS
(18) Kim; Am J Physiol 1997, V272(3 Pt 1), PE379 MEDLINE
(19) Kim; The FASEB Journal 1996, V10(14), P1646 HCAPLUS
(20) Kwon; Proc Natl Acad Sci USA 1994, V91(21), P9760 HCAPLUS
(21) Lehmann; J Biol Chem 1996, V270(22), P12953
(22) Maloff; J Clin Invest 1981, V68, P85 HCAPLUS
(23) Martz; J Biol Chem 1989, V264(23), P13672 HCAPLUS
(24) Michaud; Journal of Endocrinology 1997, V155(2), P207 HCAPLUS
(25) Moustaid; J Nutr 1996, V126, P865 HCAPLUS
(26) Muller; Biochem Pharmacol 1994, V48(5), P985 MEDLINE
(27) Muller; Horm Metab Res 1996, V28, P469 MEDLINE
(28) Mynatt; Proc Natl Acad Sci USA 1997, V94(3), P919 HCAPLUS
(29) Perusse; Obesity Research 1999, V7(1), P111 HCAPLUS
(30) Philipson; Science 1995, V270, P1159 HCAPLUS
(31) Rajan; Endocrinology 1994, V134(3), P1581 HCAPLUS
(32) Sowers; American Journal of Hypertension 1991, V4(7 Pt 2), P466S MEDLINE
(33) Sturgess; The Lancet 1985, VII(8453), P474
(34) Thomas; Science 1995, V268, P426 HCAPLUS
(35) Xue; FASEB J 1998, V12, P1391 HCAPLUS
(36) Zemel; American Journal of Hypertension 1991, V4(6), P537 HCAPLUS
(37) Zemel; American Journal of Physiology 1992, V262(3 Pt 1), PE368 MEDLINE
(38) Zemel; J Nutr 1994, V125(6S), P1715S
(39) Zemel; J Nutr 1994, V125(6S), P1738S
(40) Zemel; Proc Natl Acad Sci USA 1995, V92, P4733 HCAPLUS

L45 ANSWER 11 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN
AN **1999:454261** HCAPLUS
DN 131:98053
ED Entered STN: 26 Jul 1999
TI Methods and compositions for treating and diagnosing insulin related disorders using insulin-derived polypeptides
IN Duckworth, William Clifford; Hamel, Frederick G.
PA USA
SO PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07K014-62
ICS G01N033-68
CC 2-6 (Mammalian Hormones)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9935169	A2	19990715	WO 1999-US471	19990108
	WO 9935169	A3	19991007		
	W: AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ, DE, DE, DK, DK, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2317674	AA	19990715	CA 1999-2317674	19990108
	AU 9923138	A1	19990726	AU 1999-23138	19990108

	EP 1045860	A2	20001025	EP 1999-903019	19990108
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	BR 9906833	A	20011127	BR 1999-6833	19990108
	JP 2002500234	T2	20020108	JP 2000-527564	19990108
PRAI	US 1998-70821P	P	19980108		
	WO 1999-US471	W	19990108		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9935169	ICM	C07K014-62
	ICS	G01N033-68
WO 9935169	ECLA	C07K014/62

AB The present invention relates to methods and compns. for treating or reducing the symptoms of a disorder of absolute or relative insulin deficiency, severe insulin resistance, of lipid accumulation or excess lipid synthesis, or of protein catabolism or degradation A preferred method of treating or reducing symptoms of such a disorder includes administering a polypeptide that includes a sequence flanking an insulin degrading enzyme cleavage site of insulin. Such peptides preferably inhibit one or more activities of the complex of insulin degrading enzyme and multicatalytic proteinase. The invention also includes methods for detecting and for assessing treatments of such disorders based on measuring the activity of a complex between insulin degrading enzyme and multicatalytic proteinase.

ST insulin related disorder treatment diagnosis insulin derived polypeptide; multicatalytic proteinase insulin degrading enzyme complex inhibition

IT Muscle, disease
(atrophy; treatment and diagnosis of chronic wasting disease using insulin-derived polypeptides that inhibit the activity of the complex between insulin degrading enzyme and multicatalytic proteinase)

IT Diagnosis
(diabetes mellitus; treatment and diagnosis of insulin-related disorders using insulin-derived polypeptides that inhibit the activity of the complex between insulin degrading enzyme and multicatalytic proteinase)

IT **Lipids, biological studies**
RL: BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative)
(formation; treatment and diagnosis of disorders involving excess lipid accumulation using insulin-derived polypeptides that inhibit the activity of the complex between insulin degrading enzyme and multicatalytic proteinase)

IT Heart, disease
(infarction; treatment and diagnosis of myocardial infarction using insulin-derived polypeptides that inhibit the activity of the complex between insulin degrading enzyme and multicatalytic proteinase)

IT Diabetes mellitus
(non-insulin-dependent; treatment and diagnosis of insulin-related disorders using insulin-derived polypeptides that inhibit the activity of the complex between insulin degrading enzyme and multicatalytic proteinase)

IT Injury
(trauma; treatment and diagnosis of severe stress using insulin-derived polypeptides that inhibit the activity of the complex between insulin degrading enzyme and multicatalytic proteinase)

IT AIDS (disease)
Anti-AIDS agents
Neoplasm
(treatment and diagnosis of chronic wasting disease using insulin-derived polypeptides that inhibit the activity of the complex between insulin degrading enzyme and multicatalytic proteinase)

IT Protein degradation
(treatment and diagnosis of disorders involving protein degradation using insulin-derived polypeptides that inhibit the activity of the complex between insulin degrading enzyme and multicatalytic proteinase)

IT Antidiabetic agents
Antiobesity agents
Diagnosis
Drug screening
(treatment and diagnosis of insulin-related disorders using insulin-derived polypeptides that inhibit the activity of the complex between insulin degrading enzyme and multicatalytic proteinase)
IT Cardiovascular agents
(treatment and diagnosis of myocardial infarction using insulin-derived polypeptides that inhibit the activity of the complex between insulin degrading enzyme and multicatalytic proteinase)
IT Burn
Starvation, animal
Stress, animal
(treatment and diagnosis of severe stress using insulin-derived polypeptides that inhibit the activity of the complex between insulin degrading enzyme and multicatalytic proteinase)
IT Disease, animal
(wasting; treatment and diagnosis of chronic wasting disease using insulin-derived polypeptides that inhibit the activity of the complex between insulin degrading enzyme and multicatalytic proteinase)
IT 9004-10-8, Insulin, biological studies
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(resistance; treatment and diagnosis of insulin-related disorders using insulin-derived polypeptides that inhibit the activity of the complex between insulin degrading enzyme and multicatalytic proteinase)
IT 99542-45-7 144775-20-2
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(substrate sequence adjacent to the cleavage site for insulinase; treatment and diagnosis of insulin-related disorders using insulin-derived polypeptides that inhibit the complex between insulin degrading enzyme and multicatalytic proteinase)
IT 9013-83-6D, Insulin degrading enzyme, complexes with multicatalytic proteinase 140879-24-9D, Multicatalytic proteinase, complexes with insulin degrading enzyme
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(treatment and diagnosis of insulin-related disorders using insulin-derived polypeptides that inhibit the activity of the complex between insulin degrading enzyme and multicatalytic proteinase)
IT 9004-10-8, Insulin, biological studies 9004-10-8D, Insulin, polypeptides, that include a sequence flanking an insulin degrading enzyme cleavage site, biological studies 111479-48-2 230647-03-7 230647-04-8 230647-05-9
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment and diagnosis of insulin-related disorders using insulin-derived polypeptides that inhibit the activity of the complex between insulin degrading enzyme and multicatalytic proteinase)

=> b stng
FILE 'STNGUIDE' ENTERED AT 11:18:05 ON 03 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jul 29, 2005 (20050729/UP).

=> b home
FILE 'HOME' ENTERED AT 11:18:13 ON 03 AUG 2005

=>